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ABSTRACT
Becker, Larry J., M.S.,

1977

Microbiology

Characterization of the Immune Response in Mice Treated
With Material Toxic for Macrophages (127 pp.)
Director:

Jon A, Rudbach

RML mice were treated with Min-U-Sil or carrageenan,
both of which were toxic for macrophages. After 6 h,
the mice were immunized intravenously (i.v.) with either
lipopolysaccharide (LPS) or sheep red blood cells (SRBC).
The kinetics of the subsequent antibody responses were
determined by hemagglutination. Treatment with these
toxins prior to immunization did not suppress the pri
mary antibody response to either antigen nor did it impair
priming for a secondary antibody response. In fact,
enhanced primary antibody responses were obtained in
some macrophage impaired mice. The outcome depended on
the dose of antigen used to challenge mice and the time
of immunization after macrophage impairment. Macro
globulin (19 S) antibody production was found to be
prolonged in mice immunized during macrophage impair
ment. Secondary type antibody responses to LPS could be
elicited with one dose of LPS, if given 21 days after
macrophage impairment. From these results, a regulatory
role for the macrophage in the afferent limb of the
humoral immune response was proposed.
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CHAPTER I
INTRODUCTION
Recent investigations of the initiation and develop
ment of the immune response through studies of cellular
interactions have led to an increased awareness of the com
plexity of the immune system.

Attempts to define the role

of these cellular interactions in the initiation of the
immune response have become an active area of research in
modern immunology.

Both cell-mediated immunity and anti

body production appear to be direct results of previous
cellular collaboration.

The term "antigen reactive unit"

(ARU), has been coined by Pross and Eidnger (64) to define
the minimum complex of cells and factors necessary to pro
duce a detectable immune response in reaction to antigenic
stimulation.

A full understanding of the ARU is essential

in delineating the immune response at the molecular level,
as well as offering a means of practical immunerégulâtion.
Macrophages are perhaps the most controversial cellu
lar component of the ARU.

Since the time of Metchnikoff,

the role of macrophages in a host's resistance to disease
has remained a controversial area of research.

Early

studies into the understanding of antibody formation,
apparently indicated that the macrophages were responsible
for both the uptake of antigen and synthesis of antibody
(cf 45).

As a consequence, a great part of the research in
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immunology was devoted to evaluating the uptake of antigen
by macrophages, in addition to studying the physiology of
macrophages.

Once it was recognized that lymphocytes and

plasma cells were the cells involved in antibody syn
thesis (cf ^5), the interest in macrophages subsided
momentarily.

However, the extensive investigations of the

mechanisms of lymphocyte interactions and the molecules re
leased from immunocompetent lymphocytes have regenerated an
interest in determining the precise role(s) that macro
phages may play in the development of optimal immune re
sponses (35).

The macrophage now appears to be a key cell

in the efferent limb of cell-mediated immunity (57, 90).
However, its involvement as an essential cellular component
of the afferent limb of humoral immunity or even of cellmediated immunity has remained controversial (83).
Numerous mechanisms have been proposed for the
function(s) of macrophages as possible auxiliary cells in
the afferent limb of the immune response.

Some investi

gators view macrophages as a scavenger cell, whose primary
purpose is to engulf antigen and break it down into
immunologically nonreactive products (24, 61).

In this

role, macrophages would appear to act as a safeguard of
the immune system protecting the host from antigenic
overdose (13).

It has been shown by Pujiwara and Cinader

(34), and by others (18) that a reduction in the macro
phage population of a strain of mice which were
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resistant.to induction of tolerance led to the development
of tolerance when these animals were subsequently chal
lenged with tolerogen.
Other investigators felt that, in addition to the role
of scavenger cells, macrophages also might play a key role
in the afferent limb of humoral immunity (26, 33i 35i 38,
56, 63).

Since macrophages themselves were unable to pro

duce antibodies, it had been suggested that they might
transmit some form of information about the antigen to the
lymphoid cells and in the process "educate” them.

It was

hypothesized that these "educated" lymphoid cells then would
be capable of generating a specific antibody response.
Fishman (30) and other investigators (1, 10, 39) have
suggested that macrophages produced antigen-specific RNA
which coded for the specific antibody to be produced.
Feldmann and Palmer (27) proposed that macrophages de
graded the antigen into fragments, which were capable of
stimulating directly the lymphoid cells.

Other investiga

tors (3, 23, 32, 85, 86, 8?) have presented data which
suggested that the macrophage enhanced antigenicity by
"processing” the antigen and modifying it to a highly
immunogenic form.
Unanue and co-workers (88) have proposed that small
quantities of antigen resisted phagocytosis and tended to
persist on the surface of macrophages.

Unanue (88) and

Nossal (59) theorized that the immune response operated
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best when antigen was concentrated and focused by mono
nuclear phagocytes.

Still others have proposed that

macrophages released nutritive and regulatory factors
that modulated lymphocyte responsiveness to antigenic
stimulation (19).

Many substances have been found which

were released by macrophages in what appears to be a
true secretory process.

These included numerous enzymes,

complement proteins and a number of factors defined only
by their biological activity on other cells (15» 16, 84,
89).

Recently, it has been demonstrated that macrophages

could be replaced by their own culture supernatant fluids
or by 2-mercaptoethanol when tissue culture systems were
employed to measure antibody responses to certain anti
gens (19, 44, 51).

The possibility that 2-mercaptoethanol

might stimulate directly the transformation of mouse
lymphoid cells into blast cells had been evaluated.

How

ever, there was no evidence that 2-mercaptoethanol was a
mitogen; rather, it appeared to act by maintaining lympho
cyte viability and function.
Several investigations have focused on the role of
macrophages m

vivo in the immune response.

In general,

these studies have involved macrophage transfer experiments
(75, 78, 82) or have employed the use of agents which
either blockade the reticuloendothelial system (RES)
(29, 70, 72) or were selectively toxic for macrophages
(8, 52, 78, 81).

Studies of the immune response to antigen
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administered at the time of RES blockade (8, 29, ?1) have
determined that the extent and duration of blockade was
dependent upon the concentration and type of blocking
agent employed.

Sabet and co-workers (71, 72) have shown

a 20 fold depression in the number of antibody-forming
cells when the blocking agents were given a day or two be
fore subsequent challenge with antigen.

Studies in which

carrageenan, a high molecular weight polygalactose, was
employed as a macrophage toxin indicated that the genera
tion of the immune response was dependent upon the route
of subsequent antigenic dose (8),

If antigen was admin

istered i.v. when carrageenan was given i.p. there was no
change in the antibody response.

However, when antigen was

injected i.p. a decreased antibody response resulted.
In other studies, the immunogenicity of free antigen
versus antigen associated with macrophages has been com
pared.

Generally, it was found that antigens which were

phagocytized poorly in vivo by macrophages induced at
least a 10 fold increase in the immune response when pre
sented as the macrophage-associated form rather than the
free form (55» 77, 85).

However, a different situation

was encountered with antigens that were strongly phago
cytized by macrophages in vivo.

In this situation the

free form of the antigen induced a 2 fold increase in the
immune response when compared to a comparable amount of
the macrophage-associated antigen (21, 82).
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Katz and Unanue (4?) have shown that the increased
immunogenicity of macrophage-associated antigen may not
necessarily he due to the processing of antigen by macro
phages.

In experiments when hapten-protein conjugates

were used, it was found that fibroblasts were comparable
to macrophages in their capacity to present antigen in an
increased immunogenic form.

These authors postulated that

T-lymphocytes were triggered best by antigen bound to any
cell and that after this step, the activated T-lymphocytes
regulated the triggering of B-lymphocytes.
On the other hand, there were other situations in
which macrophages were shown to have an immunologically
suppressive effect.

A decreased immune response was ob

tained when antigen was injected into the peritoneal cavity
of mice which had been stimulated previously so that the
ascites fluid contained a high concentration of macrophages
{31).

If iodoacetate, an inhibitor of phagocytosis, was

injected into the peritoneal cavity prior to the injection
of antigen, the immune response was restored (31).
Although the experimental protocols and model systems
employed were highly variable, some general characteriza
tions about the immune response in vivo could be made from
these studies.

In order to demonstrate immunological

responsiveness in vivo, immunocompetent lymphocytes were
necessary.

That is to say when antigen-associated macro

phages were transferred into immunologically tolerant mice,

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

or into mice in which lymphoid function had been impaired
by X-irradiation, there was no detectable immunological
response (21, 55).

Investigators also have demonstrated

up to a 5 fold increase in antibody titer, when antigen
was associated with viable syngenic macrophages as opposed
to non-viable, allogeneic or xenogenic macrophages (53»
82),

Thus, these data suggested that viable genetically

compatible macrophages might also be necessary for immunocompetency in vivo.

But, in contrast to the above studies,

it has been found also that the immune response could be
inhibited partially in vivo. when normal macrophages were
injected simultaneously with macrophages containing
antigen (78, 87).
Thus, despite this great amount of experimental data
and proposed mechanisms, the role of macrophages in the
generation of antibodies has remained unresolved.

Neither

the use of in vitro nor in vivo systems appeared to have
proven a definitive role for the macrophages in the
afferent limb of humoral immunity.

Conflicting evidence

as well as conflicting conclusions continued to be elicited
by various investigations.

It was still unclear whether

macrophages were absolutely essential in the induction of
the immune response or just facilitated antigen-stimulated
lymphocyte transformation.
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8
Statement of Purpose
The purpose of this study was to determine if a
reduction in the number of sessile macrophage as well as a
reduction of their function would alter the subsequent
antibody response.

More specifically, there were two areas

of concern in this study:

(1) to determine the extent and

duration of macrophage impairment induced by various
treatment; and (2) to characterize the immune status of the
mouse at the time of maximum macrophage impairment.
The phagocytic activity of the RES in mice was charac
terized following varying regimens of treatment with
crystalline silica and carrageenan.

The kinetics of the

primary antibody response were characterized in macrophageimpaired mice and were compared with those of normal mice.
The distribution of the antigen in the macrophage-impaired
mouse was investigated also.

Subsequently the ability of

the macrophage-impaired mouse to prime for a secondary
antibody response was evaluated.

Finally, in several cases,

the qualitative type of antibody engendered in the response
was determined.
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■CHAPTER II
MATERIALS AND METHODS
Animals
All experiments were performed on 5-8 week old SwissWebster derived mice of both sexes obtained from the Rocky
Mountain Laboratory (RML) stock, Hamilton, Montana.

The

mice were housed in groups of 5 and allowed food and
water a^ libitum.
Preparation of carrageenan
Calcium carrageenan in the form of Sea Kem-9

•p

was

generously donated by Dr. Donald Renn (Marine Colloids,
Rochland, Maine).

Prior to injection, the dry carrageenan

was weighed, placed in a sterile vial and resuspended to
the desired concentration with warm (37°C) sterile phos
phate buffered saline (PBS) (0.15 M NaCl, 0.0033 M PO^^;
pH 7.2).
Preparation of silica
Silica particles, (MIN-U-SIL, Whittaker, Clark and
Daniels, Inc., NY, NY) of less than 5 urn in average size,
were used for all in vivo studies.

Further sizing

fractionation was done according to the method of Larson
(50).

Briefly, 50 g of silica were suspended in 300 ml
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of distilled water and subjected to ultrasonic vibrations
(Bronson, Danbury, Conn.) for ]0 sec.

This suspension

was diluted to a total volume of 1 ^ with distilled water,
placed in a 1 ^ graduated cylinder and allowed to settle
at room temperature (25°C) for 24 h.

Pour 250 ml aliquots

were then aspirated and placed in separate centrifuge
tubes.

Fraction III (BUS) corresponding to the 500-750 ml

portion from the top, was washed two times with distilled
water and allowed to dry in a warm (60°C) oven for 48 h.
It was determined by optical measurement, that BUS consisted
of particles of the following sizes:

2.1 urn x 2,8 urn (80^),

1.4 urn X 3.5 nm (10^), and 1.4 urn x 2.1 urn (10^) (50).
Prior to injection, the dry MUS was weighed, placed in a
sterile vial, autoclaved and resuspended to the desired con
centration with sterile PBS.
Preparation of antigens
LPS from E. coli 0113.

The lipopolysaccharide (LPS)

used in these studies was a phenol-water extract of
Escherichia coli 0113 (Braude strain) prepared as described
previously by Rudbach et al. (69).
Sheep red blood cells (SRBC). SRBC preserved in
Alsever's

solution were obtained from the Colorado Serum

Company (Denver, CO).

When prepared as an antigen for

immunization, the SRBC were washed thrice in cold (4°C) PBS
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11
and the packed cells were reconstituted to the desired con
centration with cold PBS,
Collection of sera for hemagglutination assays
Whole blood was obtained from mice anesthetized with
ether by exsanguination following an axillary incision.
The blood was allowed to clot at room temperature for
approximately 1 h and then at 4°C overnight.

The serum was

harvested by centrifugation (1,000 x g for 10 min), dis
pensed into vials, heated to 56^0 for 30 rain and stored
at -20°C.
Quantification of humoral antibodies
Antibodies specific for the LPS determinant were
measured by passive hemagglutination (67).

Briefly, SRBC

coated with LPS extracted from E. coli 0113 were used as
indicator cells (58).

For sensitization, 1 mg of LPS was

dissolved in 1 ml of 0.1 M phosphate buffer (pH 7.4) and
then placed in a boiling water bath for 2 & h.

Sensitized

SRBC were prepared by combining 0.25 ml of packed, washed
SRBC, 9.0 ml PBS and 1 ml of the boiled LPS.

This mixture

was then incubated at 37^0 for 30 min with frequent mixing.
The cells were then washed thrice in cold PBS and finally
resuspended to a total volume of 0.5 ml with micro
titer diluent (PBS containing 1% heat inactivated, SRBC-
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12
absorbed normal rabbit sera).

The sensitized SRBC were

used immediately after preparation.
Antibodies specific for SRBC were measured by direct
hemagglutination.

SRBC were washed thrice in cold PBS and

0.25 ml of the packed SRBC were then suspended to a total
volume of 50 ml in microtiter diluent.

The SRBC were used

immediately after preparation.
To each well of a microtiter plate (Linbro Chemical
Company, Inc., New Haven, CT) 0.05 ml of microtiter diluent
was added and serial two-fold dilutions of the sera were
made with 0.05 ml micro-dilutors (Cooke Engineering Co.,
Alexandria, VA).

Next, 0.05 ml of SRBC or sensitized

SRBC suspended to a final concentration of 0.5^ were added
to each well, the plate was gently agitated, covered and
placed in a humid chamber.

Hemagglutination was recorded

after incubation of the plates for 2 h at 25°C and over
night at 4°C.
Titers were expressed as values of x derived from the
equation, x = log^ (HD/2), where HD was the reciprocal of
the highest dilution of sera which produced hemagglutin
ation.

Thus, the titer was the tube number of the end

point when the first tube contained a i dilution of anti
serum.

Sera which gave no hemagglutination at the lowest

dilution tested were arbitrarily assigned a titer of 0,
ie., a dilution of i.

All serum samples were tested in
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duplicate and titers were expressed as the average titer
of both tests.
Treatment of sera with 2-mercantoethanol (2-ME)
Sera were treated with 2-ME to inactivate the hemagglutinating activity of IgM antibodies.

To the first well

of a microtiter plate were added 25 ul of serum, 25 ul PBS
and 50 ul of 0.2 M 2-ME (Sigma Chemical
This mixture was allowed to incubate
a sealed humid chamber.

Co., St. Louis, MO),

at 37°C for 30 min in

After incubation, 0.05 ml of the

microtiter diluent was added to the remaining wells and
the sera were diluted and assayed as described previously.
These experiments were interpreted on the assumption that
the residual hemagglutinating antibodies present in the sera
treated with 2-ME were all of the IgG immunoglobulin class.
PhaTOCvtic activity in vivo as measured by colloidal
carbon clearance
RES function, as demonstrated by the phagocytic
activity in vivo. was studied in both normal and treated
mice.

Data were obtained by measuring the ability of mice

to clear a solution of colloidal carbon from their blood by
using a modified procedure of Biozzi

et al. (9). The

colloidal carbon (Pelikan Cll/l431a,Koh-I-Noor,

Bloomsbury,

NJ) was suspended to a final concentration of 10 mg/ml in

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

14
PBS containing 1% gelatin (Baker Chemical Co., Phillipsburg,
NJ).

The suspension was dispensed into sterile vials and

frozen at -20^C until used.

Test animals were weighed

(Mettler Model P120, Mettler Instruments, Princeton, NJ)
and then injected intravenously with 0.1 mg of prewarmed
(37°C) colloidal carbon per gram body weight.

The mice

were anesthetized with ether (Mallinchrodt Chemical Co,,
St. Louis, MO) and were bled from the retro-orbital
plexus at 5 and 15 min after the carbon injection.

At

each bleeding 0.02 ml of blood was obtained in disposable
pipets

(Coming, Corning, NY) that had been rinsed pre

viously with a heparin (Riker Lab, Inc., Northridge, CA)
solution of 500 units/ml.

The blood samples were then

lysed in 2.0 ml of a 0.1^ NagCO^ (Baker Chemical Co.,
Phillipsburg, NJ) solution and their optical densities were
determined at 650 nm with a Coleman Jr. spectrophotometer
(Coleman Instruments, Maywood, IL).

After the 15 min blood

samples were obtained, the mice were sacrificed and the wet
weights of the liver and spleen were determined.
The phagocytic index (K) was determined for each mouse
by the following formula (52),
K = Log^Q OD at 5 min - Log^Q OD at 15 min
10 min
The phagocytic index corrected for differences in body and
organ weight ((%:), was determined for each mouse by the
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following formula (52).
K X (liver weight + spleen weight)
'
total body weight
Median Lethal Dose (LD^^) of treated and normal mice
LD^q for LPS extracted from E. coli 0113 was deter
mined for both normal and treated animals.

MUS-treated

mice received 10.0 mg of MUS contained in a total volume of
0.2 ml of PBS, intravenously (i.v.).

These mice were then

injected intraperitoneally (i.p.) with LPS contained in 0.2
ml PBS.

Carrageenan-treated animals received 5.0 mg of

carrageenan contained in 0.5 ml PBS i.p.; this was followed
by the injection of LPS i.p.

Normal mice were given PBS

in the same volumes and routes as the MUS and carrageenan,
followed by the injection of LPS i.p.

Additional controls

included mice that received only MUS or carrageenan.

All

experiments were performed on groups of 10 mice and were
terminated after 72 h.

Percent mortality of mice receiving

both MUS and LPS was computed by the following formula, for
each dose of LPS injected;

mortality in groups receiving

MUS and LPS minus mortality in groups receiving only MUS =
mortality due to LPS.

Mortality data were analyzed by

the Formal Probit Method (4).
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In vitro study of -peritoneal macrophages
Peritoneal exudate cells (PEC) were stimulated by an
injection of 2.0 ml of sterile y/> thioglycolate broth (Difco
Laboratories, Detroit, MI) into the peritoneal cavity of
mice.

After 72 h, the mice were treated with either 10 mg

of MUS i.v. or 5 mg of carrageenan i.p.

Twenty-four hours

after treatment, the mice were sacrificed and the PEC were
harvested as follows.

The abdominal area was cleansed with

alcohol and 5.0 ml of sterile double strength Eagles Minimal
Essential Media (EMEM) (Grand Island Biological Company,
Grand Island, NY) was injected into the peritoneal cavity.
The abdominal area was massaged, and the peritoneal fluid
was aspirated and placed into a chilled (4°C) silicone
(Sili-Clad, Clay Adams, Parsippany, NJ) coated tube.

The

harvested PEC were then assayed for their jjn. vitro phago
cytic activity by the method of Cutler (22).

Briefly, the

PEC were washed thrice in EMEM, counted in a hemacytometer
and adjusted to a final concentration of 1.0 x 10^ cells/ml
with EMEM containing 10^ (v/v) fresh frozen normal mouse
sera (PFNMS).

A 0.5 ml volume of this suspension was then

dispensed onto a 22 mm

2

plastic cover slip and placed in a

37°C incubator for 30 min.

After this incubation, the

cover slip was rinsed vigorously thrice in EMEM to remove
the non-adherent cell populations.

Then 0.5 ml of EMEM

containing 10^ FPMMS and 2 x 10^ Candida stellatoidea
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cells/ml was dispensed onto the cover slip and this was
followed by incubation at 37°C for 60 min.

The cover slip

was rinsed thrice with EMEM and then overlayed immediately
with 0.5 ml of EMEM containing 10^ FPNMS, and incubated at
37°C for 30 min.

After this incubation, the cover slip was

rinsed with PBS, air dried, stained with Wright's stain
and observed under oil immersion.

At least 200 cells/cover

slip were counted and the percentage of cells that had
phagocytized at least two yeast cells was determined.
The rest of the original cell suspension was centri
fuged and resuspended in 0.2 ml of FPNMS.

From this con

centrated suspension slides were prepared, stained with
Wright'8 stain and differential counts were performed.
Preparation of ^^Cr labeled LPS
LPS was labeled with hexavalent ^^Cr by a modification
of the method described by Braude et al. (11).

Ten mg of

LPS was dissolved in 5 ml water containing 1.1 millicuries
of Na^'^^CrOj^ (E. R. Squibb and Sons, Inc., Seattle, WA) and
incubated at 37°C for 48 h.

Following incubation, the

solution was dialyzed against 0.001 M NagPO;^^ (pH 7.2) at
4°C.

The dialysate was changed daily until the radio

activity of the dialysate was constant for 3 days in suc
cession.

The contents of the dialysis tube were counted in,

order to determine the specific activity, and the labeled
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LPS was diluted to a concentration of 50 ug/ml with PBS.
Immediately prior to each experiment, 0.2 ml of the labeled
LPS was counted to determine the specific activity.
All animals were injected i.v. with the labeled LPS
contained in a total volume of 0.2 ml PBS.

Radioactivity

of the whole blood and organs were measured in a well-type
scintillâtion counter (Nuclear-Chicago Corp., Des Plaines,
XL) with an efficiency of approximately %

for ^^Cr.

To

measure radioactivity, samples were placed in a glass tube
and inserted into the crystal.

Samples were counted and

corrected for background and decay.
Test for lytic activity of WUS and carrageenan treated sera
Whole blood was collected from mice anesthetized with
ether and allowed to clot for 1 h at 4^0.

The sera were

harvested, pooled and heat inactivated at 56^0 for 30 min.
Serum samples of 1 ml were added to 0.2 ml of either MUS or
carrageenan; following this, 0.2 ml of a 10^ SRBC suspen
sion was added and the mixtures were incubated for 3 h at
37°C.

After incubation, the samples were centrifuged

(1000 X g for 10 min) to sediment the SRBC, and the super
natant fluids were removed and assayed for hemoglobin levels
Hemoglobin levels
Hemoglobin levels were determined by a modification of
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the method of Hanks et al. (41).

Briefly, 10 ul of sera

were added to individual tubes containing 0.5 ml of a
benzidine base (Fisher Scientific Co., Pittsburgh, PA) pre
pared in 90fo acetic acid (E. I. DuPont, Inc., Wilmington,
DA).

To this was added 0.5 ml of a 1^ hydrogen peroxide

solution (J, T. Baker Chemical Co., Phillipsburg, NJ).

The

contents of the tubes were mixed vigorously and then incu
bated at 25^C for 20 min.

After incubation, 5.0 ml of 10^

acetic acid were added to each tube.

Following an addition

al incubation period of 10 min at 25°C, the absorbance of
the solutions were measured on a Coleman Jr. spectro
photometer at 515 ^m against a 10^ acetic acid blank.

All

samples were analyzed in duplicate.
Standard hemoglobin solutions were prepared by washing
SRBC thrice with PBS.

The washed packed SRBC were lysed

with an equal volume of water followed by the addition of
0.5 ml toluene (Eastman Organic Chemicals, Rochester, NY),
This solution was centrifuged (12,100 x g) for 10 min and
the hemoglobin concentration of the supernatent fluid
determined by the cyanmethemoglobin method (cf 5).

Standard

solutions of 5» 10, 15 and 20 mg hemoglobin/dl were pre
pared from the stock solution.
Collection of sera for passive transfer and enzymatic assays
Whole blood was obtained from mice and was allowed to
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clot at 4°C for 1 h.

The sera was harvested by centri

fugation (1000 X g for 10 min) at 4°C and enzymatic assays
performed immediately.

Sera to be used for passive trans

fer were warmed to 37°C for 5 min and 1.0 ml samples were
injected into the peritoneal cavity of normal mice.
Acid phosohatase (EG 3.1,3.3) determination
Acid phosphatase levels were determined on fresh
pooled sera by the modified method of Roy et al. (66).
Duplicate determinations of all samples were performed on a
DuPont Automatic Clinical Analyzer (ACA, Model 700,000
DuPont Co., Wilmington, DE).

Briefly, under acidic condi

tions, thymolphthalein monophosphate was hydrolyzed by
phosphatase to produce thymolphthalein.

Thé reaction was

terminated with NaOH, and the absorbance read at 600 nm.
The absorbance at 600 nm due to the thymolphthalein was
proportional to the activity of the acid phosphatase in
the sample.
Lactate dehydrogenase (EC 1.1.1.27) determination
Lactate dehydrogenase (LDH) levels were determined on
fresh pooled sera by the procedure of Gay et al. (36).
Duplicate determinations of all samples were performed on
a DuPont Automatic Clinical Analyzer (ACA).
be described briefly as follows:

The method can

LDH catalyzed the
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oxidation of L-lactate to pyruvate with the simultaneous
reduction of nicotinamide-adenine dinucleotide (NAD) to the
reduced form of nicotinamide-adenine dinucleotide (NADH).
Since other reactants were present in non-rate limiting
quantities, the change in absorbance at 340 nm due to the
appearance of NADH was directly proportional to the LDH
activity.
Plague-forming cell assay
The number of direct plaque-forming cells (PPG)
specific for LPS were quantified by a hemolytic plaque
assay (53).

SRBC coated with LPS extracted from E. Coli

0113 were employed as indicator cells.

Spleens were re

moved from mice and a single cell suspension prepared by
pressing the minced spleens through a 40 mesh stainless
steel screen into cold (4°C) double strength (2X) Eagle's
Medium (Grand Island Biological Co., Grand Island, NY)
buffered with 1.0 M Tris-HCl,

The cell suspension was

washed once with 2X Eagle's, incubated for 10 min at 25^C
with 0.83^ ammonium chloride (NHj^Cl) to lyse the erythro
cytes, and washed a second time with 2X Eagle's.

There

after, the cells were resuspended in 3 .O ml of IX Eagle's
and appropriate plating dilutions were prepared in IX
Eagle's.
Individual tubes containing 2.0 ml of 0.8^ agar
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(Bacto Agar; Difco Laboratories, Inc., Detroit MI) in IX
Eagle's and 0,2 ml of 1% DEAE-dextran (Pharmacia Pine
Chemicals, Uppsala, Sweden) were prepared in a 4^°C water
bath immediately prior to plaquing.

Next, 0,2 ml of a

JOfo suspension of SRBC coated with LPS and 0.2 ml of the
spleen cell suspension were added.

The tubes were inverted

thrice and the contents poured into plastic petri plates
and allowed to solidify.

The plates were incubated in a

humid chamber for 2 h at37°C.

Following

incubation. 3.0 ml

of guinea pig complement

(BBL Division of Bio-Quest,

Cockeyville, MD) diluted

1/10in a standard complement

diluent (6l) was added to each plate.

The plates were then

incubated for 45 min at 37^C» after which the number of
plaques on the plates were counted.

Duplicate plates of the

same test cell suspension were made and the average number
of PPG was calculated.

The PPG responses of mice were ex

pressed as the number of PPC/spleen.
Statistical analysis
When applicable, data were analyzed by the Student's
t test (4),

Differences between groups were considered

significant if p <0.05.

Antibody titers were considered

to be different if the end points were at least two tubes
apart.
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CHAPTER III
RESULTS
Effects of MUS on the •phaorocytic activity of the RES
Initial experiments were designed to determine the
route of injection and amount of MUS which would produce
maximum impairment of the RES phagocytic activity.

Evalua

tion of phagocytic activity in vivo was based upon the
ability of test mice to clear carbon particles from the
peripheral blood.

Figure 1 demonstrates the phagocytic

activity of the RES following the i.p. injection of varying
concentrations of MUS.

The ability of test mice which re

ceived MUS i.p. to clear carbon from the blood was essen
tially the same as mice which received i.p. PBS. Likewise,
multiple i.p. injections of MUS on successive days did not
affect the rate of carbon clearance from the peripheral
blood.
Unlike the i.p. route, a single injection of MUS i.v.
produced a significant ( p < 0.05)reduction in the rate of
peripheral blood clearance of carbon (Fig. 2).

A dose of

10 mg of MUS injected i.v. reduced the rate of clearance
of carbon from the blood by

Neither multiple in

jections nor increased amounts of MUS suppressed phagocytic
activity.

Intravenous injections of MUS in amounts greater

than 20 mg were fatal to more than ^0% of the experimental .
23
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Fig,

1.

Phagocytic activity of the RES following i.p.

injection of varying amounts of MUS.

All mice were tested

for RES activity 24 h after the final injection of TWS.
Normal mice received an equal volume of PBS.

Each value

represents the arithmetic mean of 5 mice.
Symbols:
Single injection of MUS
|^~

I MUS injected on 2 consecutive days
MUS injected on 5 consecutive days
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2.

Phagocytic activity of the RES following i.v.

injection of varying amounts of MUS,

All mice were tested

for RES activity 24 h after the final injection of MUS,
Normal mice received an equal volume of PBS.

Each value

represents the arithmetic mean of 5 mice.
Symbols :
Single injection of ÎWS
I—

— IMUS injected on 2 consecutive days
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animals (data now shown).

Therefore, 10 mg of MUS injected

i.v, was chosen as the standard regimen.

Hereafter, 10 mg

of MUS injected i,v. will be referred to as the standard
dose of MUS.
Effects of carrageenan on the nhaerocvtic activity of
the RES
Similar experiments were designed to evaluate the
ability of carrageenan to suppress RES activity.

The route

of injection and amount of carrageenan necessary to
achieve maximum impairment of the RES were determined from
the peripheral blood carbon clearance data.

Figure 3

represents the phagocytic activity of the RES following the
i.p. injection of carrageenan.

All amounts of carrageenan

administered i.p, produced a significant (p < 0.03) sup
pression of the ability of the RES to clear carbon from
the blood.

Maximum suppression of the phagocytic activity

of the RES was obtained with 5 mg carrageenan.

Doses

greater than 5 mg did not further suppress RES activity
but often produced ablepsia and acronecrosis,
Figure 4 represents the phagocytic activity of the RES
following the i.v. injection of carrageenan.

All concen

trations of carrageenan injected i.v. produced significant
(p<0.05) suppression of RES activity, however, con
centrations of 2 mg when administered i.v. were fatal to
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Pig.

3.

Phagocytic activity of the RES following i.p.

injection of varying amounts of carrageenan.

Test mice

received a single i.p. injection of carrageenan and were
tested for RES activity 2^ h later.
an equal volume of PBS.

Normal mice received

Each value represents the arithmetic

mean of 5 mice.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

30

0.14

0.12

tu

0.10

3
<
>

0.08

0.06

Z

<
tu

S

0.04

0.02

0.00
0

mg

1

5

10

CARRAGEENAN

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Fig,

4.

Phagocytic activity of the RES following i.v.

injection of varying amounts of carrageenan.

Test mice

received a single i.v. injection of carrageenan and were
tested for RES activity 24 h later.
an equal volume of PBS.

Normal mice received

Each value represents the

arithmetic mean of 5 mice.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

3:

0.14

0.1 2

LU

=) 0.10
<
>
0.08

Z

0.06

<
LU

S

0.04

0.02

0.00
0.0
mg

0.5
1.0
CARRAGEENAN

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

33

100^ of the test mice.

Therefore, a dose of 5 mg. carra

geenan injected i.p. was used in all further experiments;
hereafter this will he referred to as the standard dose of
carrageenan.
Duration of suppression of RES activity following treatment
with MUS
The duration of suppression of RES activity by MUS was
evaluated by injecting a group of mice with the standard
dose of MUS and subsequently, testing them in groups at
varying intervals for their ability to clear colloidal
carbon.

As shown in Fig.,

, significant (p<0,05) suppresr-

sion was observed by 2 h after the administration of MUS,
and RES activity remained suppressed for 4 days.

Maximum

suppression was observed at 6 h and continued at this level
for at least 24 h.

A gradual recovery of RES activity

occurred following the single i.v, dose of MUS and clearance
values, equivalent to those obtained in normal mice, were
obtained by day 5.
Duration of RES sunnression following treatment with
carrageenan
The duration of suppression of the RES following
carrageenan treatment was evaluated in the same manner as
MUS.

Mice were injected with the standard dose of
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Fig.

5.

with MUS,

Duration of RES suppression following treatment
Test mice received a single i.v. Injection of

10 mg MUS at time 0 and were tested at various times for
their ability to clear carbon from the peripheral blood.
Normal mice received an equal volume of PBS.

Each value

represents the arithmetic mean of 5 mice.
Symbols ;
L / / /

Normal range of oC value
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carrageenan, and then tested at varying times for their
ability to clear colloidal carbon from the peripheral blood.
Results are shown in Fig. 6.

Within 2 h of the carrageenan

injection, RES activity was suppressed significantly
(p< 0 ,05) and remained suppressed for 4 days.

Maximum

suppression was observed at 6 h and continued at this level
for 48 h.
When Pig, 5 and 6 are compared, the kinetics of sup
pression obtained after MUS and carrageenan treatment
seemed to be similar.

Both phagocytic indexes dropped to a

minimum mean phagocytic clearance value of 0.0? + O.OO5
within 6 h after treatment.

The suppression persisted 24 h

with MUS and 48 h with carrageenan, after which a linear
recovery occurred and normal phagocytic clearance values
were obtained by day 5.
Effects of MUS and carrageenan on phagocytosis in vitro
Since phagocytosis experiments carried out in the
whole mouse may reflect a reduction in the phagocytic
activity of only the macrophages fixed in situ, it was of
concern to determine whether wandering macrophages were
also impaired.

In the following experiment, peritoneal

exudate cells were harvested from normal mice and from mice
which had been treated with the macrophage toxins.

The

cells were counted and evaluated for their ability to
phagocytize heat-killed Candida stellatoideae cells.
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Fig.

6.

Duration of RES suppression following treatment

with carrageenan.

Test mice received, a single i.p. injec

tion of 5 mg carrageenan at time 0 and. were tested at various
times for their ability to clear carbon from the peripheral
blood.

Normal mice received an equal volume of PBS,

value represents the arithmetic mean of 5 mice.
Symbols :
Normal range of oC value
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Table I shows that 24- h after MUS or carrageenan treatment,
the total number of macrophages harvested from the peri
toneal cavity was lower than normal.

Concurrent with

enumeration, cells were also evaluated for viability by
trypan blue exclusion,

A lower percent of viable cells

were obtained from MUS-treated and carrageenan-treated
mice as compared with normal mice.

The predominant cell

type obtained from normal and MUS-treated mice were lymph
ocytes, whereas, the predominant cell type in carrageenantreated mice were polymorphonuclear cells (PMN),

When

macrophages from MUS-treated and carrageenan-treated mice
were incubated with heat-killed Ç. stellatoideae. the
yeast were phagocytized less effectively than by macro
phages from control mice which had been injected with only
PBS.

Thus, not only were fewer viable macrophages ob

tained from the mice treated with MUS and carrageenan but
those that were obtained, had lessened phagocytic activity.
Distribution of radiolabeled LPS in normal and macronhageimpaired mice
The carbon clearance data demonstrated clearly that
following the treatment of mice with MUS, there was a
suppression in the ability of the RES to clear carbon
particles from the peripheral blood.

Similarly, the carbon-

clearing ability of the RES in carrageenan-treated mice was
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Table

1

The Effect of MUS and Carrageenan
on Peritoneal Exudate Cells

C/)

o'

3

CD

O

Group

Cells/ml

Absolute
Lympho
cytes

ë'

Macro
phages

Poly
morphs

Viability
cytic
Index

#
Macro
phages

i
3
CD
"n
c
p
3.
*
CD
S
■o

Normal^

1.2 X 10^

55

43

MUS®

1.3 X 10^

63

D
C.
a
o

■D

O
3"
CJ
CD

2

5.2 X 1 0 ^

96

77

3^

3

4.4 X

10^

85

54

f
Normal

1.3

X 10^

57

42

1

5 . 5 X 10^

95

78

Carrageenan^

1.7 X 10^

6

10

84

1 . 7 X 10^

82

47

Q.

mice/group
"CO
D

^Trypan Blue exclusion

c
n
C/)

^Percent of adherent cells (macrophages) containing at least 2 Candida stellatoidea.
^PBS injected i.v.
®10 mg KUS injected i.v.
^PBS injected i.p.
-5 mg carrageenan injected i.p.

-po

4 l

impaired.

Experiments were performed to determine if the

clearance of an antigen was also affected.

Therefore, LPS

was radiolabeled with ^^Cr as described in the Materials
and Methods section.

The radioactive LPS (LPS^^) was in

jected i.v. into mice previously treated with the standard
dose of MUS or carrageenan.

Control mice received PBS by

identical routes.
The ability to clear the LPS^^ by mice exposed to
either macrophage toxin was dramatically impaired (Table 2
and 3).

By 5 min following the i.v. injection of LPS"*^ into

normal mice, only about

of the total injected concen

tration could be recovered in whole blood.

However, in

mice treated previously with MUS prior to the i.v, in
jection of LPS^, about k-0% of the antigen injected was
present in whole blood.

Similarly, carrageenan-treated

mice retained about h-jfo of the injected LPS"’*' in the circu
lating whole blood after 5 min.

The concentration of LPS^^

within the circulating whole blood in all groups diminished
with time.

However, the rate of LPS^^ clearance from the

blood in mice exposed to MUS or carrageenan was less than
the clearance rate in normal mice.
As seen in Table 2, LPS^^ was quantified also in vari
ous organs.

Prior to counting, the individual organs were

rinsed with PBS but were not perfused.

Therefore, the

counts in the organs obtained while the peripheral blood
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Table 2

■D

Tissue Distribution 6f ^^Cr-labeled LPS in Normal and Macrophage-impaired Mice

CD

C/)
C/)

Nanograms of LPS
Group

Organ

Time of Assay
5 min.

30 min.

Ih

6h

24h

48h

Normal

Blood®
Spleen
Liver
Kidneys
Lungs

364
78
783?
65
27

272
56
7709
45
29

108
41
7690
36
9

84
42
7406
37
7

48
54
7434
31
13

28
46
7340
32
7

a
MUS^

Blood®
Spleen
Liver
Kidneys
Lungs

4068
973
1644
207
174

3276
836
1568
216
3 I8

2880
778
2180
238
77

1824
787
2424
189
44

544
887
3196
118
75

248
864
3290
119
63

Carrageenan®

Blood®
Spleen
Liver
Kidneys
Lungs

4324
223
1278
186
190

3900
206
1849
206
273

4164
204
1760
296
220

ND
ND
ND
ND
ND

ND
ND
ND
ND
ND

8

3
ci'

3
3"
CD
CD

■D
O
Q.
C
a
O
3
"O
O
CD

Q.

■D
CD

ND^
I®
ND
1®
ND

®A11 mice received 10,000 ng of ^^Cr-labeled LPS l.v, at time 0,

■u
C/)
C/)

Nanograms of LPS were calculated by the following formula:
ng of LPS = (10,000 ng LPS) (counts/organ) / (100,394 counts/10,000 ng LPS]
All samples were counted for the same period of time and were corrected for back
ground and decay. Each value represents the arithmetic mean of 3 mice/group,

®0,5 ml of blood was counted.
blood volume of 2.0 ml

Amount of LPS was calculated assuming a circulating

^Mice received 10 mg MUS i.v. at time -6 h.
®Mice received 5 mg carrageenan i.p, at time -6 h.
^N.D,

Not done

r\5
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Table

3

Percent Tissue Distribution of ^^Cr-labeled LPS

■D
CD

in Normal and Macropbage-impaired Mice
C/)

o"

3
O

a
Group'

Organ
5 min.

8

ci'
Normal

3
3"

CD
CD

■D
O
Q.
C
a
O
■D
O

Percent of Total Injected LPS

,
ms^

3

Carrageenan

CD

Q.

Time of Assay
30 min.
1 h
6 h

24 h

48 h

Blood®
Spleen
Liver
Kidneys
Lungs

3.6
0.8
78.4
0.7
0.3

2.7
0.6
77.1
0.5
0.3

1.1
0.4
76.9
0.4
0.1

0.8
0.4
74.1
0.4
0.1

0.5
0.5
74.3
0.3
0.1

0.3
0.5
73.4
0.3
0.1

Blood®
Spleen
Liver
Kidneys
Lungs

40.7
9.7
16.4
2.1
1.7

32.8
8.4
15.7
2.2
3.2

28.9
7.8
21.8
2.4
0.8

18.2
7.9
24.2
1.9
0.4

5.4
8.9
3 2 .0
1.2
0.8

2.5
8.6
32.9
1.2
0.6

Blood®
Spleen
Liver
Kidneys
Lungs

43.2
2.3
12.8
1.9
1.9

39.0
2.1
18.5
2.1
2.7

41.6
2.0
17.6
3.0
2.2

KD^
ND
ND
ND
ND

ND
ND
■ ND
ND
ND

ND
ND
ND
ND
ND

®A11 mice received 10,000 ng of ^^Cr-labeled LPS i.v. at time 0.

■D
CD

C/)

_ ng of LPS in organ
^Percent of total Injected LPS ^
ng of LPS injected

X 100

o"
3

®0.5 ml of blood was counted.
blood volume of 2.0 ml.

Percent of LPS was calculated assuming a circulating

^Mice received 10 mg IfOS i.v. at time - 6 h.
®Mice received 5 mg carrageenan i.p. at time - 6 h,
^N.D,

Not done.
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LPS* concentration was high, probably reflected some LPS*
contained in the blood in addition to the specific
localization of LPS* within these various organs.

It can

be seen that a relatively small amount of the total LPS*
injected was found in the kidneys and lungs.

However, the

liver and spleen showed considerable localization of LPS*.
In normal control mice 78^ and 0.8^ of the total injected
LPS* were found in the liver and spleen respectively, after
5 min,

MUS-treated mice revealed l6^ LPS* recovered from

the liver while

was recovered from the spleen.

It was

probable that the increased amount of LPS* seen within the
spleen in MUS-treated mice represented an increased
localization of LPS* and not merely entrapment of peripheral
blood, since this value remained constant throughout the
experiment and did not decrease proportionally with the
amount of LPS* in the peripheral blood.

Similarly, in

carrageenan-treated mice, 13^ and 2% of the injected LPS*
was recovered from the liver and spleen, respectively,
after 5 min.

Again it was assumed that the increase in

splenic LPS* represented a true increased localization of
LPS*, since the increased values persisted at this level
throughout the duration of the experiment.
Localization of LPS* within the liver of treated mice
increased with time throughout the experiment.

After 48 h

the amount of LPS* recovered from the liver of MUS-treated
mice had increased to 33^ of that injected, while in
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4*5
carrageenan-treated mice approximately 20^ of the injected
LPS* was localized in the liver.
mice retained

By comparison, normal

of the injected LPS* at 48 h.

Thus, additional evidence was obtained which showed
that MUS and carrageenan had impaired macrophages.

The

increase in splenic localization of LPS* was relatively
greater than in other tissues in treated mice.

Organs

which were examined for localization of LPS* included
stomach, intestines, bladder, mesenteric lymph nodes,
inguinal lymph nodes, axillary lymph nodes and popliteal
nodes.

However, none of these appeared to be specific sites

for localization of LPS* in either normal or treated mice.
These data may be important in light of further observa
tions presented in the next sessions.
Sensitivity of MUS and carrageenan-treated mice to LPS
toxicity

It is well established that agents which either block
ade or reduce RES function render animals more susceptible
to the toxicity of LPS (37, 93).

Based on this observa

tion, the median lethal dose (LD^q ) to LPS should reflect
the in vivo functional capacity of the RES,

Mice were in

jected with 10 mg MUS i.v, or with 5 mg carrageenan i.p.
These injections were followed by the i.p, injection of
varying amounts of LPS,

Controls consisted of animals re

ceiving only MUS or carrageenan but no LPS and normal mice
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receiving only the LPS.

The mice were observed and deaths

recorded at 12 h intervals until termination of the experi
ment at 72 h.
Figure ? shows that mice receiving LPS concurrently
with either MUS or carrageenan were more susceptible to the
toxicity of LPS than were normal mice,

MUS-treated mice

were approximately 40 times more sensitive to LPS toxicity
4
than normal mice. An LD^^ value of 2.7 x 10 ng of LPS
(Pig. 8) was obtained with TiUS-treated mice, whereas normal
mice exhibited no deaths even at the highest dose of LPS
(1

X

10^ ng).

Carrageenan-treated mice were approximately

3,000 times more sensitive to LPS toxicity with an LD^^
value of 3.7 x 10^ ng of LPS.

Hence, the LD^^ values

obtained with MUS-treated and carrageenan-treated mice
provided additional evidence that impairment of the EES had
occurred.
Primary antibody responses of mice friven antigen at
varying times dur in/? macronhage impairment
Other authors have presented data indicating that the
time at which mice were challenged with antigen during the
course of macrophage impairment was critical to the re
sultant antibody response (52, 72, 81).

Therefore, experi

ments were designed to expose mice to antigen at varying
intervals prior to and after the dose of macrophage toxins.
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Fig.

7.

Sensitivity of MUS or carrageenan-treated mice to

LPS toxicity.

Mice were injected with 10 mg of MUS i.v, or

5 mg of carrageenan i.p. at time 0, followed by the in
jection of varying amounts of LPS i.p.

Normal mice received

PBS by identical routes followed by the injection of LPS
i.p.
Symbols :
......

Normal mice
Carrageenan-treated mice
MUS-treated mice

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

48

10 0

90

80

><

I—

ut
>
»- 4 0

<
3

S 30
3
O
20

10
O0
LOG

10

LPS

DOSE

(mg)

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

49
Mice were challenged with antigen as early as 24 h prior
to the standard dose of MUS (carrageenan) or as late as 5
days after the injection of macrophage toxin.

Mice were

bled 5 days after the dose of antigen and their sera were
pooled and titrated for antibody.
As shown on Table 4, if either LPS or SRBC antigen was
given prior to or concurrently with either macrophage toxin
there was no observable difference in the resultant anti
body titer as compared to normal mice.

The only observable

difference in titer between normal mice and mice injected
with macrophage toxins occurred when mice were challenged
with 0.2 ml of 0,03% SRBC suspension 6 h and 24 h after ex
posure to either macrophage toxin.

As seen on Table 4, mice

that received MUS or carrageenan demonstrated an enhanced
antibody titer to the lower dose of SRBC,

Mice that re

ceived antigen later than 24 h after exposure to macro
phage toxins did not demonstrate an observable difference
in the antibody response.
It was found in this experiment that the only observa—
ble difference in the antibody response occurred when mice
received a sub-maximal SRBC antigenic challenge 6 h and
24 h after exposure to MUS or carrageenan.

However, at no

time during RES suppression by either macrophage toxin was
there a decrease in antibody response,

regardless of the

time of exposure to the toxin.
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Table 4
Primary Antibody Responses of Mice Immunized at
Varying Intervals During Macrophage Impairment

■O
CD

C/)

(/)
o
3"
8

Grout)

Antibody Titer

Antigen

Time of Antigen Administration (hours)
-24 -6
0
6
24
48
72
96

c5'

120

3
CD

C
3.

PBS

3"

CD

■SO

I
C
a

10 ug LPS
0,1 ug LPS
10^ SRBC

7

8

8

7

7

8

7

7

8

5

5

6

4

5

4

5

5

8

7

8

7.5

8

7

7.5

0.05^ SRBC

7.5
4

5
8

4.5

5

4

4

4

4.5

4

5

10 ug LPS

7

8

8

7

6

7

7

6

6

10$ SRBC
0.05$ SRBC

7

8

8

7

7

7

7

8

7

5

5

5

6

6

4.5

5

5

4

0.1 ug LPS

6

4

5

5

5

4

6

4

6

10$ SRBC

7

7

8

7.5

7

7

8

8

7

0.05$ SRBC

4.5

4

4

6

6

4

3.5

4

4.5

o

3

■O
O

o
c
■o
CD

MUS

Carrageenan

^PBS, 10 mg MUS or 5 mg carrageenan injected at time 0 (5 mice/group).
^Mice were bled 5 days after antigenic challenge, sera pooled and titers determined,
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Kinetics of the -primary antibody response to LPS and SRBC
in r-KJS-treated mice
The kinetics of the primary antibody response to LPS
was evaluated in MUS-treated and normal mice.

Animals

received the standard dose of MUS and 6 h later were chal
lenged i.v. with antigen.

Control groups received an

equal volume of PBS i.v, and were challenged similarly
with antigen.

Groups of 5 mice were bled daily, their sera

pooled and evaluated for antibodies to LPS by passive hemag
glutination.

As shown in Fig. 8, there does not appear to

be a difference in either the kinetics or in the magnitude
of the resulting antibody response.

With either dose of

LPS (10 ug or 1 ug), initial antibody responses could be
detected after 3 days.

Maximum antibody titers in treated

mice, as well as normal mice were obtained on day 5 and
persisted at this level for the duration of the experiment.
Sera obtained on the fifth day were also treated with
2-mercaptoethanol (2-ME) in order to estimate the relative
amounts of antibody in the IgM and IgG classes.

Serum

samples were treated with 2-ME, as described in the
Materials and Methods section, and then titrated for the
presence of specific antibody activity.

When the titers of

the sera before and after treatment with 2-ME were compared
it was possible to determine the relative contribution if
IgM and IgG antibodies to the total response.

Following
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Fig.

8,

Kinetics of the primary antibody response of

normal and MUS-treated mice to LPS.

Mice were injected

at time 0 with 10 mg MUS or PBS i.v. followed 6 h later
with the injection of LPS.

Mice were bled on 8 consecu

tive days and titers were determined by passive hemag
glutination,

Each point represents the antibody titer

of sera pooled from 5 mice/group.
Symbols :
-A

A

Normal mice
MUS-treated mice

A.

Mice injected with 10 ug LPS, i.v.

B.

Mice injected with 1 ug LPS, i.v.
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5^
treatment with 2-ME there was no residual antibody titer
detectable by passive hemagglutination.

Therefore, the

antibody response for both groups of mice was primarily IgM.
Treated and normal mice were also evaluated for their
ability to respond to the T-cell dependent SRBC antigen.
The experimental protocol was the same as that described
previously for LPS, except that SRBC was used as the anti
gen,

With the high antigenic dose of SRBC (0.2 ml of 10^

SRBC) initial antibody responses could be detected 2 days
after antigenic stimulation in both groups of mice.
(Fig, 9 A),

After the second day the kinetics of the anti

body response were similar for both groups until app rox i
mately the seventh day.

At that time the MUS-treated mice

attained a peak titer of 11, while the normal mice peaked
at a titer of 8.5.
maximal dose of SRBC

W h e n mice were challenged with the sub(0.2 ml of 0.05^ SRBC)

both the kinet

ics and magnitude of the antibody response varied.

Circu

lating antibodies to SRBC could be detected in macrophageimpaired mice at 2 days, but we re not detectable in normal
mice until 4 days after antigenic stimulation (Pig. 9 B ) .
Mot only were circulating antibodies demonstrable earlier
in macrophage-impaired mice, but the maximum antibody
response was 4 fold (end point dilution of 192 vs 48) higher
than the maximum antibody response generated by normal mice.
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Fig,

9.

Kinetics of the primary antibody response of

normal and MUS-treated mice to SRBC,

Mice were injected

at time 0 with 10 mg MUS or PBS i,v. followed,6 h later by
the injection of SRBC,

Mice were bled on 8 consecutive

days and titers were determined by hemagglutination.

Each

point represents the antibody titer of sera pooled from
5 mice/group.
Symbols ;
A

^

Normal mice
MUS-treated mice

A.

Mice injected with 0,2 ml of 10^ SRBC, i,v.

B.

Mice injected with 0,2 ml of 0,05^ SRBC, i.v.
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Kinetics of the primary antibody response to LPS and SRBC
in carrageenan-treated mice
The kinetics of the primary antibody response to LPS
was evaluated in carrageenan-treated and in normal mice.
Mice were injected with the standard dose of carrageenan or
PBS and 6 h later were injected i.v. with antigen.

Because

of the increased susceptibility to LPS in the carrageenantreated mice, only one dose of LPS (0.1 ug) was used.

As

shown in Fig. 10, there was not any difference in either
the kinetics or in the magnitude of the antibody response
between macrophage-impaired and normal mice.

Initial anti

body responses could be detected in both groups, 3 days
after the injection of antigen.

Peak titers for both

groups were reached on day 5 and titers tended to persist
at this level for the duration of the experiment.
The primary antibody response of carrageenan-treated
mice to SRBC was evaluated in a manner similar to that
described above.

Mice received the standard dose of carra

geenan or PBS followed 6 h later by the i.v. injection of
SRBC.

With the larger dose of SRBC (0,2 ml of 10^ SRBC),

both the time of development and magnitude of the resulting
antibody titers were similar in both carrageenan-treated
and normal mice (Pig, 11 A).

Initial antibody responses

were demonstrable 2 days after antigenic challenge.

Peak

titers in both groups were achieved 5 days after antigenic
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Pig.

10,

Kinetics of the primary antibody response of

normal and carrageenan-treated mice to LPS.

Mice were

injected at time 0 with PBS or 5 mg carrageenan i.p.
followed 6 h later by the injection of LPS.

Mice were

bled on 8 consecutive days and titers were determined by
passive hemagglutination.

Each point represents the

antibody titer of sera pooled from 5 mice/group.
Symbols :
Normal mice, injected i.v, with 0.1 ug of LPS
Carrageenan-treated mice, injected with 0.1 ug
of LPS
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Pig, 11.

Kinetics of the primary antibody response of

normal and carrageenan-treated mice to SRBC,

Mice were

injected at time 0 with PBS or 5 mg carrageenan i,p,
followed 6 h later by the injection of SRBC,

Mice were

bled on 8 consecutive days and titers were determined by
hemagglutination.

Each point represents the antibody

titer of sera pooled from 5 mice/group.
Symbols :
-'A
#

Normal mice
Carrageenan-treated mice

A,

Mice injected i.v, with 0,2 ml of 10^ SRBC,

B,

Mice injected i.v, with 0,2 ml of 0,05/^ SRBC,
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challenge and tended to persist at this level for the dura
tion of the experiment.

When mice received the sub-maximal

dose of SRBC (0,2 ml of 0.05^ SRBC) both the kinetics and
the magnitude of the antibody response were altered
(Fig. 11 B).

Initial antibody responses were detectable 1

day earlier in carrageenan-treated mice than in normal mice.
Maximum anti-SRBC titers were obtained 5 days after the in
jection of antigen in both groups, however, there was an
approximate 5 fold (end point dilution of 256 vs 48) in
crease in the magnitude of the antibody response of the
carrageenan-treated mice.
Primary antibody responses of normal and macrophageimmired mice to various concentrations of SRBC
During the characterization of the kinetics of the pri
mary antibody response to the SRBC antigen, it was observed
that MUS-treated or carrageenan-treated mice demonstrated
higher antibody titers in their sera than normal mice.
Further experiments were performed to determine if the en
hanced primary antibody response to SRBC was dose dependent.
Groups of 5 mice were treated with the standard dose
of MUS or carrageenan.

Control groups received an equal

volume of PBS by identical routes of injection.

After 6 h,

mice were injected with varying amounts of SRBC.

Five days

after the dose of antigen, the mice were bled, their sera
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pooled and titrated.
Figures 12 and 13 demonstrate that as the dose of
SRBC was decreased,

the resulting antibody titer decreased

but still remained at an enhanced level in the MUS-treated
and carrageenan-treated mice w h e n compared to normal mice.
In contrast,

normal mice exhibited a more profound drop in

the resultant antibody titer as the dose of antigen was
decreased.

Anti-SRBC titers of 7.5»

with 0.2 ml of 10^,
normal mice,
titers of 9.5»

6 and 4 were obtained

1% and 0.05^ SRBC, respectively, in

MUS-treated mice demonstrated anti-SRBC
8 and 7 to similar doses of antigen.

Anti

body titers of 7, 7 and 6.5 were obtained respectively in
carrageenan-treated mice.

Thus,

the primary antibody r e 

sponse to the SRBC antigen were consistently higher in mice
previously treated with MUS or carrageenan.

The sera from both normal and macrophage-impaired mice
were treated with 2-ME,

As shown in Figs. 12 and 13» all

mice receiving the primary antigenic challenge dose of
0.2 ml of 10% SRBC, possessed 2-ME resistant antibody
activity.

Normal mice exhibited a 12 fold (end point

dilution of 384 vs 32) reduction in hemagglutinating
activity following treatment of the sera with 2-ME, whereas
MUS-treated mice showed only a 6 fold (end point dilution
of 1536 vs 256) reduction in hemagglutinating activity.
Similarly, carrageenan-treated mice showed an 8 fold (end
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Pig.

12.

Primary antibody responses of normal and MUS

treated mice to varying doses of SRBC,

Mice were injected

at time 0 with PBS or 10 mg of MUS i.v, followed 6 h later
with the i.v. injection of SRBC.

Mice were bled 5 days

later and titers were determined by hemagglutination.

Each

value represents the antibody titer of sera pooled from
5 mice/group.
Symbols :
Antibody titer of sera
I

— I Antibody titer of sera following treatment
with 2-mercaptoethanol

A.

Normal mice

B,

MUS-treated mice
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Fig.

13. Primary antibody response of normal and

carrageenan-treated mice to varying doses of SRBC,

Mice

were injected at time 0 with PBS or 5 mg of carrageenan
t
i.p. followed 6 h later with the i.v, injection of SRBC,
Mice were bled 5 days later and titers were determined by
hemagglutination.

Each value represents the antibody titer

of sera pooled from 5 mice/group.
Symbols :
Antibody titer of sera
^ Antibody titer of sera following treatment
with 2-mercaptoethanol
A,

Normal mice

B.

Carrageenan-treated mice
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point dilution of 25é vs 32) reduction in titer following
treatment of sera with 2-ME.

Thus, the sera of mice

immunized during macrophage impairment contained more IgG
than did the sera of normal mice,
MUS or carrageenan-treated mice were also capable of
generating a 2-ME resistant antibody response to an anti
genic challenge dose of 0.2 ml of 1^ SRBC.

Mice immunized

during macrophage impairment with MUS or carrageenan demon
strated a 16 to 8 fold (end point dilution of 512 vs 32 and
256 vs 32) reduction in the total antibody titer following
2-ME treatment, respectively.

Conversely, in normal mice

immunized with this dose of SRBC no 2-ME resistant anti
bodies were found.

When the antigen concentration was re

duced to a 0.05/^ SRBC suspension no 2-ME resistant activity
was present in either the macrophage impaired or control
group.
Thus, when the higher dose of SRBC (0.2 ml of 10^
SRBC) was employed, the resulting antibody response in both
normal and treated animals was a mixture of IgG and IgM
antibodies.

Conversely, with a lower dose of SRBC (0.2 ml

of 0.05^) only IgM antibodies were generated in both nor
mal and treated animals.

At the intermediate SRBC dose,

specific antibodies of IgM and IgG classes were generated
only in the mice exposed to macrophage toxins prior to
antigenic challenge, while normal control mice responded
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with antibody production in only the IgM class.
Release of Hemopclobin following: exposure of SRBC to MUS
or carrap:eenan
Feldmann and co-workers (27, 28) had shown previously
that the production of an antibody response to SRBC in vitro
was dependent upon three cell types;
B-lymphocytes and macrophages.

T-lymphocytes,

They were also able to

demonstrate, with in vitro experiments, that macrophages
were required only when intact SRBC were used as antigens.
If the SRBC were sonicated and presented to only the T cells
and B cells in the soluble form, it was noted that antibody
production would occur without the presence of macrophages.
Thus, it appeared that the soluble form of the SRBC antigen
was macrophage independent in vitro, whereas the intact
SRBC antigen was macrophage dependent.
Since primary antibody responses to SRBC in macrophageimpaired mice were equal to or greater than the antibody
response of normal mice, it was of importance to determine
if this enhancement possibly was due to a lytic action of
MUS or carrageenan on the SRBC in vivo.

If this was

occurring the role of the macrophage as a possible antigen-processing cell would be circumvented.

Therefore, MUS

and carrageenan were analyzed in vitro for their ability
to lyse SRBC.
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As shown in Table 5i there was no difference in the
free hemoglobin levels between control sera and sera plus
in vivo concentrations of MUS or carrageenan.

If either

macrophage toxin were capable of inducing lysis of the
SRBC, this should have been reflected in a higher free
hemoglobin level.

Since this was not observed with either

MUS or carrageenan, it could be surmised that the in vivo
amounts of macrophage toxins employed in the present
study were not lytic to SRBC.
Passive transfer of sera from normal and macrophageimpaired mice into normal mice which received LFS or SRBC
The destruction of macrophages in vivo by MUS or
carrageenan should result in the release of intracellular
enzymes into the peripheral blood.

Measurement of these

enzymes would offer a method for determining the extent of
macrophage destruction that had occurred.

Therefore,

experiments were designed to assay the sera from mice re
ceiving MUS or carrageenan for acid phosphatase and lactate
dehydrogenase (LDH) levels.

These same sera were then

transferred passively into normal mice, which subsequently
were challenged with antigen and their antibody titers
determined.
Mice were treated with the standard dose of MUS or
carrageenan.

Control mice received an equal volume of

PBS by identical routes of injection.

The mice were
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Table

5

Release of Hemoj^lobin Following Exposure of
SRBC to MRS
or Carrageenan
Free
Group

Incubation Mixture
A
B
C
serum

serum

serum

12

serum

serum

SRBC

12

serum

PBS

SRBC

12

serum

water

SRBC

20

water

water

SRBC

520

MUS

serum

MUS

SRBC

11

Carra
geenan

serum

Carra
geenan

SRBC

12

Controls

A.

1 ml of serum or water.

B.

0.2 ml of serum, PBS, water

C,

0.2 ml of serum or 10^ SRBC

MUS or carrageenan.
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sacrificed 24 h after the exposure to macrophage toxins
and were bled by axillary incision.

Blood was collected

in chilled tubes, refrigerated for 1 h at 4°C and the sera
removed.

Enzymatic assays as described in the Materials

and Methods section were performed immediately on the fresh
harvested sera.

Normal mice then received 1,0 ml of the

appropriate sera i,p, followed immediately by the i.p,
injection of LPS or SRBC,

Mice were bled 5 days later and

serum antibody titers determined.

The i.p, route of in

jection of both sera and antigen was chosen to avoid cir
culatory overload and to allow intimate contact in vivo
between antigen and the enzymatically active sera.
As shown in Table 6, the serum levels of acid phos
phatase and LDH activity in mice receiving either macro
phage toxin were higher than in control mice.

The acid

phosphatase values in treated mice were 2-3 times normal
while LDH values showed a 12-15 fold increase.

The release

of acid phosphatase from the lysosomes of phagocytic cells
occurs not only as the direct result of cell death, but
can be triggered by phagocytosis or after contact with
antigen-antibody complexes.

However, the cytoplasmic

enzyme, LDH, is not secreted or released unless the cell
has been destroyed (91).

Therefore, measurement of LDH

gives a better indication of the amount of cell destruction
that has occurred in vivo.
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Table

Serum Enzyme Levels

6

of Normal and

Macrophage-impaired Mice®'

Group

Acid
Phosphatase (lU/L)

Lactate
Dehydrogenase (lU/L)

Normal^

0.53

148

MUS°

1.08

I860

Normal^

0.50

166

Carrageenan®

1.56

2506

®Enzymatic assays were performed 24 h after the mice were
injected with either PBS, MUS or carrageenan. Each
value represents the enzymatic activity of the sera
pooled from 50 mice.
^Mice were injected i.v. with PBS.
®Mice were injected i.v. with 10 mg MUS.
^Mice were injected i.p. with PBS.
®Mice were injected i.p. with 5 mg carrageenan
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Figures l4, 15 and l6 show the anti-LPS and anti-SRBC
titers of mice receiving normal or treated sera with
standard doses of antigen.

No observable differences were

seen in the antibody titers between recipients of either
type of serum in any of the groups.

Although enzymatic

analyses showed macrophage autolysis and release of intra
cellular enzymes, the increased enzymatic activity and/or
the release of soluble factors from damaged macrophages
did not affect the in vivo antigenicity of either LPS or
SRBC.
Secondary response of normal and macrophage-impaired mice
to LPS
It was shown previously that MUS or carrageenantreated mice responded with a primary humoral antibody
response equally as well or better than normal mice to
the T-cell independent LPS antigen.

It was of interest

to determine if a secondary antibody response could be
induced as efficiently in mice receiving the primary anti
genic dose during macrophage impairment as in normal mice.
Mice were treated with the standard dose of MUS or
carrageenan and 6 h later received the priming dose of
LPS (1,0 ug or 0,1 ug) i,V,

A standard secondary dose of

LPS (1,0 ug) was administered 21 days later.

Control mice

received an equal volume of PBS by identical routes of
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Fig.

14.

Primary antibody responses of mice to a 1.0 ug

dose of LPS given after receiving sera from normal and
macrophage-impaired mice.

Mice were injected at time 0

with PBS, normal mouse sera or macrophage impaired mouse
sera i.p. followed immediately by the injection of 1.0 ug
of LPS i.p.

Mice were bled 5 days later and titers were

determined by passive hemagglutination.

Each value

represents the antibody titer of sera pooled from 5 mice/
group.
^Mice received only antigen.
^Mice received antigen and 1.0 ml PBS.
°Mice received antigen and 1.0 ml of sera obtained
from mice treated with PBS 24 h earlier.
^Mice received antigen and 1.0 ml of sera obtained
from mice treated with 10.0 mg of MUS 24 h earlier.
®Mice received antigen and 1.0 ml of sera obtained
from mice treated with 5 mg of carrageenan
24 h earlier.
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Pig.

15. Primary antibody responses of mice to.0,2 ml of

0.05% SRBC after receiving sera from normal and macrophageimpaired mice.

Mice were injected at time 0 with PBS,

normal mouse sera or macrophage-impaired mouse sera i,p.
followed immediately by the injection of 0,2 ml of 0 ,05^
SRBC i.p.

Mice were bled 5 days later and titers were

determined by hemagglutination.

Each value represents the

antibody titer of sera pooled from 5 mice/group.
^Mice received only antigen.
^Mice received antigen and 1.0 ml PBS.
^Mice received antigen and 1.0 ml of sera obtained
from mice treated with PBS 24- h earlier,
^Mice received antigen and 1,0 ml of sera obtained
from mice treated with 10.0 mg of MUS 24 h earlier,
®Mice received antigen and 1,0 ml of sera obtained
from mice treated with 5 mg of carrageenan
24 h earlier.
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Fig. 16.

Primary antibody responses of mice to 0,2 ml

of 10% SRBC after receiving sera from normal and
macrophage-impaired mice.

Mice were injected at time 0

with PBS, normal mouse sera or macrophage-impaired mouse
sera i.p. followed immediately by the injection of 0,2 ml
of 10% SRBC i.p.

Mice were bled 5 days later and titers

were determined by hemagglutination.

Each value

represents the antibody titer of sera pooled from
5 mice/group.
^Mice received only antigen.
^Mice

received antigen and 1.0 ml PBS.

°Mice

received antigen and 1.0 ml of sera obtained

from mice treated with PBS 24 h earlier,
^Mice received antigen and 1.0 ml of sera obtained
from mice treated with 10,0 mg of MUS 24 h
earlier.
®Mice received antigen and 1.0 ml of sera obtained
from mice treated with 5 mg of carrageenan
24 h earlier.
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81
injection.

Additional controls included mice receiving

only the primary or secondary dose of antigen.

All mice

were bled 4 days after receiving the secondary antigen and
their sera were pooled and titered.
As seen on Tables 7, 8, 9 and 10, there was no dif
ference in the ability to elicit a secondary antibody
response in mice primed with antigen during macrophage
impairment as compared with normal mice.

The magnitude of

the secondary responses to both doses of priming antigens
were equal in macrophage-impaired and normal mice.

No

residual antibody titer was detected following treatment of
the sera with 2-ME, thus indicating that the secondary
response generated in both treated and normal mice was pre
dominately an IgM antibody response.
Of most interest, however, were the results generated
within the control groups.

The anti-LPS titers were con

siderably higher in mice treated with macrophage toxins
and given no primary dose of LPS prior to the secondary in
jection of antigen than in normal mice.

The antibody

responses generated in the macrophage-impaired group ap
proached the magnitude of the secondary antibody responses
of normal mice which received two doses of LPS,

Qualita

tively, these antibodies to LPS were demonstrated to be of
the IgM type.

Thus, mice only exposed to either MUS or

carrageenan 21 days earlier responded to the single dose of
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treatment with 2-ME.
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LPS in a manner* similar to normal mice receiving both
primary and secondary doses of antigen.

In summary, then,

it was shown that the antibody responses generated in mice
receiving antigen 21 days after exposure to MUS or
carrageenan, resembled a secondary antibody response.
Due to the consistent finding that secondary-type
antibody responses could be elicited by a single dose of
antigen in mice exposed to macrophage toxins 21 days prior
to immunization, it was of interest to examine the spleens
of these animals in order to determine the number of
specific antibody forming cells.

Groups of mice were

treated with either MUS or carrageenan and after 21 days
received a single injection of LPS,

Five days after immu

nization the spleens were removed, single cell suspensions
were prepared, and the number of direct plaque forming
cells (PPG) determined as described in Materials and
Methods.

Blood samples were also collected from these

mice and were tested for hemagglutinating antibody titers.
In normal mice which received both a primary and
secondary antigenic dose, the number of direct PPG/spleen
was about 25 times higher than that of normal mice which
received only one immunizing dose of LPS (Table 11),
Therefore, normal mice were primed to LPS with the primary
injection of antigen, and a specific population of antiLPS memory cells generated.

These observations were also

reflected in the antibody titers.

Normal mice which
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received only a primary antigenic dose, developed cir
culating antibody titers of 4.5, whereas, normal mice
which received both a primary and secondary antigenic dose
developed titers of 10.5.
The number of direct PFC/spleen found in mice treated
with either MUS or carrageenan 21 days prior to re
ceiving the only injection of LPS was approximately ID
times that of normal mice receiving only one injection of
antigen.

Titers of the circulating antibody level revealed

that mice treated with macrophage toxins 21 days prior to
the primary injection of antigen developed antibody titers
that were over 50 fold higher than those observed in nor
mal mice which received only one dose of antigen.

Thus, the

increased level of circulating antibodies within the mice
exposed to macrophage toxins was equivalent to the anti
body levels found in normal mice, which had received both
a primary and secondary injection of LPS.

It is of interest

that the circulating antibody titers were equivalent, but
the number of direct PPC/spleen was approximately three
times lower in macrophage impaired mice than in normal
mice.

Approximately 13,000 direct PFC/spleen were found

in normal mice during the typical secondary antibody re
sponse, whereas, only about 5,000 direct PFC/spleen were
found in the macrophage-impaired mice during the secondary-,
type antibody response.

Thus, it appears that either the
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rate of antibody synthesis is increased in mice previously
exposed to macrophage toxins or else a major amount of
antibody production has occurred in other lymphoid organs.
Secondary antibody response of normal and macrophageimpaired mice to SRBC
Due to the difficulty in eliciting an IgG type
secondary antibody response to the LPS antigen, it was of
interest to determine what type of secondary response would
be elicited to the SRBC antigen.

Experimental protocol was

identical to the secondary antibody response studies of
LPS, except that mice received a primary immunizing dose of
0.2 ml of a 10^ SRBC suspension i.v. followed 21 days later
with the secondary immunizing dose of 0.2 ml of 10% SRBC
suspension i.p.
Mice which received the primary SRBC antigenic dose
during macrophage impairment were capable of eliciting a
secondary antibody response to SRBC.

This response was both

quantitatively and qualitatively equal to the secondary
antibody responses of normal mice (Table 12).

Only anti

bodies that were resistant to 2-ME were detectable in all
the groups of mice tested, indicating that antibodies of
the IgG type predominated.

Therefore, the capability of

the immune system to prime for a secondary antibody re
sponse to the SRBC antigen was not impeded in mice exposed
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to macrophage toxins prior to receiving the primary anti
genic dose.
Both control and treated mice possessed residual anti
bodies to SRBC 25 days after receiving only the primary
immunizing dose.

Within the control mice these antibodies

were determined by 2-ME resistance to be of the IgG type.
Although the predominant antibody detectable within the
macrophage-impaired mice was also IgG there were, in
addition, 2-ME sensitive antibodies indicating that the
production of IgM antibodies were prolonged in the macro
phage -impaired groups.
The primary antibody responses in mice which received
antigen 21 days after exposure to either macrophage toxin
were of considerable interest.

Normal mice responded

to the primary immunizing dose of SRBC with both IgM and IgG
antibodies in approximately equal proportions.

Mice which

were exposed to a single dose of either MUS or carrageenan,
21 days prior to immunization with SRBC, while making
quantitatively a primary level response, produced only an
antibody response of the IgM type.
In summary, mice exposed to macrophage toxins prior to
receiving a primary dose of SRBC were as capable as nor
mal mice in the capacity to prime for a secondary antibody
response to 0.2 ml of a 10^ SRBC suspension.

Residual

antibody titers 25 days after exposure to antigen were found
to be only IgG in normal mice, whereas macrophage-impaired
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mice still possessed some IgM as well as IgG type anti
bodies.

If a single dose of SRBC was given 21 days

following exposure to either MUS or carrageenan, only an
IgM antibody response was induced, whereas normal mice
responded with both IgM and IgG immunoglobulins under
similar conditions.
Secondary antibody responses of normal and macrophageimpaired mice to varying priming doses of SRBC
Further experiments were performed to determine if
mice treated with macrophage toxins were as efficient as
normal mice in their ability to prime for secondary anti
body responses with smaller amounts of SRBC than were
tested previously.

As seen in Table 13, both mice treated

with macrophage toxins and normal mice were primed to
similar degrees at all doses of SRBC antigen tested.
Typical secondary antibody responses, indicated by a higher
titer and/or IgG type antibody, were elicited in both
groups given the secondary injection of antigen.
Residual primary antibody titers were detectable only
within the groups of mice receiving a primary immunizing
dose of 0.2 ml of 0.01% SRBC.

These residual antibodies

were found to consist of both 2-ME sensitive and 2-ME
resistant types in mice receiving either MUS or carrageenan.
Normal mice not only had a lower concentration of residual
antibodies 25 days after immunization, but the hemaggluti-
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Table

13

S e c o n d a r y A n t i b o d y fieaponscs of forti.al a n d Kacrophare-imp,aired M i c e

to

Var i o u c Priminp: D o s e s of SRBC

A n t i b o d y Ti t e r

Secondary

Pri m a r y
Group

Treatment
(Day 21)

(Day 0)

Total

2 -ME R e s i s t a n t ®

PBS (I.v.)
MUS
PBS (i.p.)
Carr.a K e e n a n

SRBC
SH 3 C
SR 3 C
SR3C

0.01%)
0.01%)

SRBC
SHBC
SRBC
SRBC

PBS (I.v.)
Kl!S
PBS ( i . p . )
Carrageenan

SRBC
SR.IC
SREC
SRcC

0.01%)
0.01%)
0.01%)
0.01%)

None
None
None
Hone

3
5

10
11
12

PBS (i.v.)
MUS
PBS (i.p.)
Carrageenan

S RBC
SRBC
SRBC
SRBC

0.001%)
0.001%)
0.001%)
0.001%)

S RBC
S RBC
SHBC
SRBC

7
7
8
7.5
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14
15
16

PBS (i.v.)
MUS
PBS (i.p.)
Carrageenan

SRBC
SRB C
SRB C
SRBC

0.001%)
0.001%)
0.001%)
0.001%)

None
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None
None

0
0
0
1

0
0
0
0
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PBS ( i . v . )
WJS
PBS (i.p.)
Carrageenan

SRBC
SRBC
SRB C
SREC

0.0001%)
0.0001%)
0.0001%)
0.0001%)

SRBC
SRBC

6.5
6

3
4

S RBC

7
7

4
4

22
23
24

PES (i.v.)
MI'S
PBS (i.p.)
Carrageenan

S RRC
S RBC
SRBC
S RRC

0.0001%)
0.0001%)
0.0001%)
0.0001%)

Hone
Hone
Hone
Hone

0
0
0
0

0
0
0
0

25
26
27
28

PES (i.v.)
MTS
PBS (i.p.)
Carrareenan

H one
[.one
N one
None

SRBC
SRB C
SRB C
SRBC

5

0
0
0
0

1
2

3
4

5
6
?

8
9

19
20

21

0.01%)
0.01%)

7

5.5
7

10

6

7.5
9

7
0

3
0
4

2
6

SRBC

•5
5
5
5

6

5
6

^ K i c e w e r e treated a t time 0 w i t h e i t h e r 10 m g MUS I.v. or 5 mg c a r r a g e e n a n i.p.
C o n t r o l m ice r e c e i v e d an eq u a l v o l u m e of PBS by I d entical routes of injection.
^ M i c e r e c e i v e d 0.2 .nl of
° M i c e r e c e i v e d 0,2 ml
‘^Each v a l u e r e p r e s e n t s

the

indicated SRBC

suspens Ions

of a 0.05SÎ SRBC s u s p e n s i o n
the a n t i b o d y

i.v.

I.p.

titer of sera pooled

"^Rncb v a l u e reprerent.s the a n t i b o d y t i t e r of sera p o o l e d
t r e a t m e n t w i t h 2-F.E.

from 5 mice/group.
from 5 inice/rroup a f t e r
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nation properties were destroyed after 2-ME treatment,
indicating that these were I^M antibodies. Therefore, mice
which had received the primary immunizing dose of SRBC
during macrophage impairment maintained a higher concen
tration of residual antibodies as well as antibodies of
both the IgG and IgM classes.
Thus, priming for secondary antibody responses to the
particulate SRBC antigen was not suppressed if mice re
ceived priming doses of antigen during impairment of macro
phage phagocytosis.

Interestingly, if mice were immunized

(0,2 ml of 0.01^ SRBC) during macrophage impairment both
IgG and IgM classes of antibodies persisted 25 days later.
However, in normal mice only IgM antibodies were present.
Thus, the quantity and quality of antibody remaining in
circulation 25 days after a primary injection of antigen
appeared to be dependent upon the dose of antigen and the
number of functional macrophages at the time of immuni
zation.

More antibody in total and especially more of the

IgG class was produced and maintained in mice which had been
injected with MUS or carrageenan.
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CHAPTER IV
DISCUSSION
In recent years there have been several hypotheses
concerning the possible role of macrophages in the in
duction of humoral antibody responses.

Derived from these

hypotheses were suggestions that macrophages caused effects
ranging from complete abrogation to an acceleration of the
antibody response (25, 27, 47, 83).

In the present study,

the role of the macrophage in humoral immunity was evalu
ated in vivo. This was done by testing the immune response
of mice in which macrophages had been impaired by macro
phage toxins.

Mice which received the macrophage toxins

prior to immunization were still capable of producing nor
mal to supranormal humoral antibody responses to T-cell
independent (LPS) and T-cell dependent (SRBC) antigens.
However, when the primary antibody response to the T-cell
dependent antigen was compared between normal and macro
phage -impaired mice, a relationship was observed which was
dependent on the dose of antigen.

This relationship

appeared to affect not only the kinetics and magnitude of
the antibody response but also the class of antibody pro
duced.

In addition, typical secondary antibody responses

could be elicited from mice primed with antigen during
macrophage impairment.

Moreover, the macrophage toxins

themselves appeared to be capable of priming mice for
95
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specific secondary responses to LPS.

Thus, -it appeared that

macrophages might have a role in modulating the immune re
sponse in vivo by controlling the antigenic dose and pro
moting long term stimulation rather than being absolutely
necessary for "processing" the antigen,
Imoairment of in vivo nhagocvtic activity
Although there was no method available which would
deplete completely the mice of macrophages it had been well
established that silica and carrageenan were capable of
selectively injuring and destroying substantial numbers of
macrophages (2, 17).

Numerous investigators have employed

these agents, both in vivo and in vitro. to dissect the
afferent and efferent limbs of humoral as well as cellmediated immunity (8 52, 73» 92).

However, despite the

studies on immunological phenomenon in animals treated with
silica or carrageenan, relatively little data had been
accumulated on the degree and duration of impaired phago
cytic activity iR vivo.

Most commonly, the i.p. route of

injection had been used for giving the macrophage toxins
to test animals (40, 60, 92).

It was possible that mate

rials given by this route of injection could have damaged
only the wandering mononuclear phagocytic cells and left
the fixed macrophages intact.

Dissemination of the i.p,

injected toxin was considered to be dependent upon the
ingestion of the cytotoxic particles by macrophages in
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route to other areas of the body.

Persal and Weiser (60)

were able to demonstrate disseminated silica particles
within the spleen, liver and bone marrow of mice following
the repeated i.p. injection of high concentrations of
silica.

However, no attempt was made to correlate the

dissemination of silica particles with the reduction in
phagocytic activity in vivo.
Impairment by MUS.

In the present studies, when various

regimens of MUS were given to mice by the intraperitoneal
route, essentially normal carbon clearance values were ob
tained.

Since mice were exposed repeatedly to daily i.p.

injections of MUS, it was felt that a sufficient amount
(total dose of 250 mg) and time (6 days) was allowed for any
dissemination to have occurred.

The dissemination of MUS

with resulting macrophage destruction was not detected by
either in vivo carbon clearance studies or at autopsy.
Large quantities of MUS were found to be sequestered within
the peritoneal cavity.

Although microscopic examination was

not performed, the MUS grossly appeared to be encased in a
fibrous-like tissue membrane, often with adhesions to the
liver, mesentery and peritoneal membranes.

It had been well

documented that silica-treated macrophages released a
fibroblast stimulating factor (14, 49) which might have
been responsible for the rapid sequestering of MUS given
by the intraperitoneal route; this could allow for a quick
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recovery of the RES.
The localization of MUS observed within the peritoneal
cavity and the essentially normal carbon clearance data in
dicated either that dissemination of a sustained cytotoxic
concentration of MUS into areas where it could exert its
effect on in situ macrophages did not occur, or else the
release of MUS was slowed to a rate at which the host could
compensate for its cytotoxic effects.

In either case, the

functional phagocytic capacity of the RES within the animal
was not suppressed.
The ability of MUS injected intravenously to suppress
the in vivo carbon clearance capacity of the RES correlated
well with the results of other investigators (52).

In the

present study, RES suppression was observed by 2 h after
mice were given i.v, doses of MUS.

With a single treatment,

the phagocytic capacity of MUS-treated mice remained sup
pressed for

days.

Levy (52) had demonstrated previously

that peritoneal mononuclear cells, harvested from mice
treated with silica by the i.v. route, showed impaired
phagocytosis of SRBC in vitro. Similarly in this study
mononuclear cells, which were adherent to plastic and were
obtained from the peritoneal cavity of mice treated with
MUS i.v. 2^■ h earlier, were less efficient in their ability
to phagocytize Ç. stellatoideae cells in vitro. Thus,
data were obtained from phagocytic studies in vivo and
in vitro that the i.v. injection of MUS was capable of
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impairing the phagocytic activity of the fixed as well as
the wandering macrophage populations.
Since MUS was not metabolized in vivo, it was thought
that it could be used as a long term macrophage toxin.

That

is to say, after ingestion of the particle the macrophage
would undergo autolysis releasing the toxic particle to be
rephagocytized by other cells.

This process would be re

peated until the host could sequester the MUS in a fibrous
or in a granulomatous lesion.

However, this study demon

strated that the suppressive effect of i.v, administered
MUS on phagocytosis was maintained for only 4 days.

There

fore, it appeared that the toxic MUS particles were
sequestered from the host rather quickly and the cytotoxic
action either abolished or compensated for by the host.

Re

generation of a functional macrophage population, capable
of yielding normal In vivo carbon clearance values, occurred
within 5 days.

Hence, a single injection of MUS could be

used as a selective cytotoxic agent to evaluate the in
ductive phage of immunological responses which occurred in
less than 5 days, but this treatment could not chronically
suppress macrophage function in vivo without repeated
injections.
In summary, the MUS preparation employed within this
study was capable of impairing the phagocytic capacity of
the RES,

It was found .that the i,p. route of injection for

this macrophage toxin, even with multiple injections of high
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doses (50 mg/day for 5 days) did not suppress the ability
of the RES to remove carbon from the peripheral blood.
Conversely, the i.v, administration of a single dose of
MUS was found to suppress the ability of the RES to clear
carbon as early as 2 h after its administration.

Maximum

impairment of phagocytic activity was obtained 6 h
after the i.v. administration of MUS and this impairment
was maintained for 4 days.

Prom analysis in vivo and

in vitro, it was shown that a substantial number of the
phagocytic cells of the RES had been destroyed or im
paired.

From the above data, it was concluded that MUS

could be used to analyze the role of macrophage phagocytosis
in the induction of the immune response in vivo.
Impairment by carrageenan.

Carrageenan, a high molecular

weight polygalactose extracted from sea algae,was also used
as a macrophage toxin in this study.

It had been shown to

exert its toxic effect by inducing changes in the permea
bility of the lysosomal membrane resulting in autolysis of
the phagocytic cell (2, 17),
Carrageenan was capable of suppressing the phagocytic
activity of the RES when administered by either the i.v.
or i.p. routes.

However, mice would tolerate an i.v. dose

of only 1 mg carrageenan,

A solution of carrageenan was

quite viscous even at low concentrations and the viscosity
alone could have caused the deaths observed in mice which
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received 2 mg.

Indirect evidence suggested that dissemi

nation of the carrageenan occurred very rapidly throughout
the host when the toxin was given i.p.

Data in support of

this, were from observations that suppression of the EES
was observed within 2 h following i.p. injection of
carrageenan.
Concurrently with the reduced carbon clearing capacity
of

situ macrophages, it was also found that the wandering

macrophages harvested from the peritoneal cavity of mice
treated with carrageenan were less effective in their
ability to phagocytize in vitro. Therefore, as was found
with T4US, carrageenan was also found to be capable of im
pairing the phagocytic activity of the fixed as well as the
wandering macrophage populations.
Changes in the serum enzyme concentrations of mice
treated with either macrophage toxin also indicated that
cell destruction had occurred.

Weissman et al, (91) had

shown previously that up to 25% of certain acid hydrolases
were released from the lysosomes of phagocytic cells during
phagocytosis.

Hence, increased serum levels of enzymes

normally contained within the lysosomes of phagocytes
might not necessarily reflect cell destruction.

Therefore,

in this study both the lysosomal enzyme, acid phosphatase,
and the cytoplasmic enzyme, LDH, were measured.

Both

enzymes were found to be elevated in mice exposed to macro
phage toxins.

The concomitant increase of both acid
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phosphatase and LDH indicated that the enzyme levels found
in the peripheral blood were due to cell autolysis.
In addition, two other assay systems were used to
demonstrate the in vivo cytotoxicity of MUS and carra
geenan.

The first system employed radiolabeled LPS in

jected into normal and mice treated with the macrophage
toxins.

The tissue distribution of LPS found in normal

animals correlated well with the results of other investi
gators (11, 12, 5^, 68).

It was demonstrated in this study

that over 75^ of the LPS was found in the liver of normal
mice, while less than \% was associated with any of the
other tissues assayed.

On the other hand, less LPS was

found in the livers of mice treated with macrophage toxins
and large amounts of LPS were retained in the peripheral
blood of macrophage-impaired mice.

Higher levels of LPS

were consistently found in the spleens of macrophageimpaired mice than were found in normal mice.

Thus, the

treatment of mice with macrophage toxins had impaired the
ability of the macrophages to phagocytize not only parti
culate materials, such as carbon or yeast cells, but also
the colloidal antigen (LPS) which was subsequently tested
for immunogenicity in these mice.
The other auxiliary system used to demonstrate RES
impairment was a measurement of the sensitivity of macro
phage -impaired mice to the toxicity of LPS.

It had been

well established that agents which impaired the phagocytic

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

103
activity of the RES increased the sensitivity of impaired
animals to the toxic effects of LPS (6, 20),

The results

obtained in this study indicated that mice treated with
MUS or carrageenan were respectively, 40 and 3000 times
more susceptible than normal mice to the lethal effects of
LPS.
Thus, by numerous independent assay systems this study
showed that both MUS and carrageenan under controlled con
ditions were capable of impairing the phagocytic capacity
of the RES in a reproducible and consistent manner.

This

suppression was not permanent with either toxin, but it
persisted for only 4 days.

Maximal suppression of RES

activity occurred 6 h after mice received either toxin and
persisted at this level for at least 24 h and 48 h after
treatment with MUS and carrageenan, respectively.

There

fore, it was felt that if mice were exposed to antigen 6 h
after treatment with either macrophage toxin any role the
macrophage might play in the afferent limb of humoral anti
body formation should, be altered.

If phagocytosis of anti

gen was a prerequisite for the induction of an optimal
immune response In vivo then mice receiving antigen during
impaired phagocytosis should either (1) not be able to
respond with antibody production, (2) respond with antibody
production but, at a sub-optimal level, or (3) show a de
layed antibody response until a competent macrophage
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population was regenerated.
Primary antibody responses
In other investigations (8, 52, 72, 80) it was observed
that primary antibody responses could be suppressed in
animals treated with agents which impaired the RES if the
impairment occurred prior to immunization.

Thus, it was

inferred that phagocytosis, processing, and/or presentation
of antigen to lymphocytes by macrophages were essential
events for the induction of optimal antibody responses.
This study did not demonstrate any suppression of the pri
mary antibody response to either LPS or SBRC antigens re
gardless of the time at which mice were exposed to macro
phage toxins in relation to the antigenic dose.

The only

observable difference between macrophage-impaired mice and
normal mice was the increased primary antibody response of
the impaired mice to low immunizing doses of the SRBC anti
gen.

This increased antibody response was induced only when

mice were immunized 6 h and 24 h after exposure to macro
phage toxins.

Interestingly, this was the period during

which the phagocytic capacity of the RES was most severely
suppressed.

Thus, it appeared that a decreased functional

macrophage population in vivo could be correlated with the
increased antibody response demonstrated in this study,
Keller (48) had shown with antibody responses generated
in vitro that alteration of the macrophage/lymphocyte ratio
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could modify mitogen-induced lymphocyte proliferation,

A

macrophage/lymphocyte ratio of ten macrophages per one
lymphocyte consistently blocked proliferation and even a
ratio of one macrophage per one lymphocyte was inhibitory.
Conversely, ratios of one macrophage per 25 or 100 lympho
cytes resulted in an increased proliferative response.
Since both MUS and carrageenan have been shown to be
selectively toxic for macrophages and not lymphocytes
(2, 17) it could be assumed that the macrophage/lymphocyte
ratio was decreased in treated mice.

Thus, it appeared

that there may have been a direct competition between macro
phages and lymphocytes for antigen or that the macrophages
suppressed proliferation of antigen-stimulated lymphocytes
in normal mice.
When the tissue distribution of radiolabeled LPS was
quantified, consistently higher than normal amounts of
LPS were found within the spleens of macrophage-impaired
mice.

Similarly, others (75» 76) have demonstrated an

increased localization of chromium-labeled SRBC within the
spleens of macrophage-impaired mice.

It appeared that

if circulating antigen was not removed and sequestered by
macrophages, it might be capable of binding directly to
splenic lymphocytes.
In other investigations (8, 52, 72) it had been demon
strated that the alterations in primary antibody responses
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of macrophage-impaired mice were correlated with both the
routes of macrophage toxin administration and antigen pre
sentation.

Bice et al. (8) demonstrated normal to enhanced

splenic PPG when SRBC antigen was given i.v. to mice
treated previously with carrageenan i.p.

However, when SRBC

antigen was given i.p. to mice treated similarly with carra
geenan, the number of splenic PPG was reduced greatly.
Other investigations (80, 81) also had demonstrated a de
creased number of splenic PPG when both carrageenan and
SRBC antigen were given i.p.

It was concluded that the

cytotoxic action of carrageenan was confined to the peri
toneal cavity and did not affect macrophages throughout
the animal.

This allowed intravenously administered anti

gen to be processed by the unaltered functional splenic
macrophages.

In opposition to the above data, the results

of the present study indicated that carrageenan was not
confined to the peritoneal cavity.

In fact, its effect

was disseminated rapidly throughout the host as evidenced
by the impairment of intravenously administered colloidal
carbon.

An explanation for the decreased responses ob

served in the previously cited work could be that 24 h
following the i.p. injection of carrageenan, the predomi
nant cell type within the peritoneal cavity was PMN,
Therefore, the decreased anti-SRBG responses observed
could have been due to antigen degradation by the PMN

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

107
rather than the lack of macrophage processing.
In summary, other studies have shown that the injection
routes of both the macrophage toxin as well as the antigen
appeared to be critical in elucidating the role of the
macrophage as an effecter cell of humoral immunity.

Also

recent studies by Benner and Vanoudenaren (7) demonstrated
that the systems used for quantitative assessment of the
immune response were important when attempting to evaluate
the total humoral response.

For example, specific PPG were

found in substantial numbers in organs not normally
assayed such as the bone marrow.

The present investigation

has demonstrated that primary antibody responses could be
induced at normal or a supranormal levels during macro
phage impairment.

This was evaluated by determinations of

the total circulating antibody response.

It was felt that

measurement of circulating antibody titers truly reflected
the immunological status of the whole animal.

Furthermore,

it appeared that there might have been direct competition
between macrophages and other immunologically active cells.
This phenomenon was especially evident when macrophageimpaired mice were given a sub-optimal dose of SRBC,

Thus,

it appeared that macrophages could function to modulate the
immune response in vivo by regulating the amount of antigen
available for the triggering, rather than by some processing
step.

It also appeared that by controlling the amount of

antigen available for antigenic stimulation, macrophages
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might play a major role in influencing the resultant class
of antibody synthesized.
Secondary antibody responses
Relatively little data had been obtained from studies
in vivo, which evaluated the ability of macrophage-impaired
animals to be primed for secondary antibody responses,
Stevenson and Stavitsky (79) demonstrated that the primary
antibody response to T2 phage could be suppressed with
anti-macrophage globulin (AHG), However, this regimen of
AMG did not impair the secondary responsiveness of these
animals.

This indicated that if animals were immunized

during impaired macrophage function the priming mechanism
for secondary antibody responses was not affected.
Likewise, the present study demonstrated that mice
treated with MUS or carrageenan before the primary immuni
zation appeared to develop typical secondary antibody re
sponses when challenged with a second dose of LPS.

Since

immunization with this regimen of LPS elicited anti
bodies of only the IgM class, it was impossible to evaluate
the secondary response by a change in antibody class.

How

ever, the kinetics and the magnitude of the response in
dicated that a typical secondary antibody response to LPS
had been elicited.

Mice, primed during macrophage impair

ment with varying doses of SRBC, responded with typical
secondary responses when challenged with a second dose of
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SRBC.

These antibody responses were characterized by an

increased antibody titer and/or by antibody production of
the IgG class. Thus, it appeared that priming with LPS or
SRBC for a secondary antibody response occurred as effi
ciently in mice which received the primary immunization
during macrophage impairment as in normal mice.
In the course of running controls of the effect of MUS
and carrageenan during the time of priming mice for sec
ondary antibody responses, several observations were made.
Mice treated with either toxin 21 days prior to immunization
with SRBC developed higher than normal primary antibody
responses.

It was determined that macrophage-impaired mice

responded with antibodies of only the IgM class, regardless
of the immunizing dose.

However, normal mice responded to

a high dose of SRBC (0.2 ml of 10^) with both IgM and IgG
class antibodies, whereas with a low immunizing dose of
SRBC (0.2 ml of 0.05J») only antibodies of the IgM class were
generated.

This elevation of the antibody response in

animals treated with macrophage toxins had been noted by
others (33» 4-2, 46, 62),

The present study did not evalu

ate further the reason for the higher response obtained
from mice exposed to macrophage toxins 21 days prior to
immunization with SRBC.
More interesting were the observations made when mice .
were exposed to macrophage toxins 21 days prior to
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immunization with LPS.

It was noted that a secondary-type

antibody response could be elicited with only one dose of
antigen.

From correlation of hemagglutination and PPG

data, it appeared that this response might be due to in
creased antibody production in committed lymphocytes rather
than the development or expansion of a memory cell popula
tion.

Thus, regulatory factors which controlled the rate

of negative feedback mechanism might have been altered by
(1)

the decreased number of functional macrophages,

(2)

factors released from the impaired macrophages, or

(3)

the macrophage toxins themselves.
The possibility that B-cells werederepressed during

macrophage impairment or that major antibody production had
occurred in organs other than the spleen could not be
disregarded.

Alternately, the possibility that the MUS and

carrageenan preparations employed within this study were
contaminated with LPS cannot be excluded totally.

However,

the fact that (1) anti-LPS titers could never be elicited
from mice injected with only MUS or carrageenan, (2) direct
anti-LPS splenic PPG were not demonstrated in mice receiv
ing only MUS or carrageenan, (3) similar observations have
been noted by other investigators (33) employing different
antigens, and finally (4) the probability that both the MUS
and carrageenan would be contaminated with the same chemo- .
type of LPS made the possibility of LPS contamination very
remote.
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As observed, in the present study, as well as in other
investigations (46), immunization during macrophage
impairment appeared to prolong the macroglobulin response
to both LPS and SREC antigens.

Consistently higher titers

with evidence of IgM class antibodies were detected in
macrophage impaired mice 21 days after immunization with a
single dose of LPS or SRBC,

Thus, especially when the

anti-SRBC was evaluated, it appeared that the rate and
duration of IgM production might be altered in mice exposed
to macrophage toxins prior to immunization.

The antibody

response observed in normal mice appeared to involve a
switch from the early biosynthesis of predominantly macroglobulin antibody to the production of 7 S molecules.

Con

versely, this switch to ? S antibody production did not
occur as efficiently when mice were immunized during macro
phage impairment.
Henry and Jerne (43) had shown that IgM could function
as a positive feedback molecule.

That is to say, antibody

contained within the 19 S fraction when given prior to a
moderate dose of SRBC antigen increased the antibody re
sponse 10-15 fold.

It appeared that the enhancement as well

as the prolongation of the primary macroglobulin antibody
response observed within this study might be directly re
lated to the decreased functional macrophage population
during immunization.

Macrophages might function by

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

112

controlling the epitope density of antigen available for
triggering other cells in the immunological sequence.
During macrophage impairment, antigen was not sequestered
and, therefore, was available to repeatedly stimulate the
immunological active cells.

This repeated stimulation

might result in the enhanced production of the positive
feedback IgM molecule and may explain the enhanced, as well
as the prolonged antibody responses observed in this study.
Concluding remarks
The precise mechanism by which macrophages partici
pate in the immune response still remains to be eluci
dated.

From this study it appeared that macrophages may

modulate, in vivo, the immune response by controlling the
amount of antigen available for direct stimulation of other
cells in the immunological sequence.

Thus, the quantity

as well as the quality of the immune response, may be con
trolled indirectly by macrophages acting as a sequesterant
of antigen and not by increasing directly the immuno
genicity of the antigenic molecule via some processing
step.

These observations were consistent with current

studies which indicated that a small amount of antigen
remained on the surface of the macrophage and was not
catabolized (88).

Also, other studies demonstrated that

macrophage-associated antigen could stimulate lymphocytes

(y4, 78, 82).

Such a mechamism would insure an economical
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response by reserving a small amount of antigen to stimulate
the immune system over a prolonged period.

Therefore, it

appeared that phagocytosis, processing, and presentation of
antigen by macrophages to lymphocytes were not prerequisites
for the induction of immune responses in vivo. The role
played by the macrophage would be one of a passive bystander
rather than as an active participant.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER V
SUMMARY
The effects of macrophage toxins on the immune re
sponse of mice in vivo were investigated,.

It was deter

mined that a reduction of the functional macrophage popu
lation did not suppress the humoral immune response to
either the T-cell independent LPS antigen or the T-cell
dependent SRBC antigen.
Two specific macrophage toxins, MUS and carrageenan,
were determined to be capable of reducing phagocytic
activity in vivo.

The degree of suppression varied with

each toxin and depended on the route of administration.
TWS was capable of reducing phagocytic activity in vivo
only when it was administered i.v.

On the other hand,

carrageenan reduced the phagocytic activity when administer
ed either i.v. or i.p., although the i.p. route allowed the
administration of a larger dose with fewer toxic side
effects.

The initiation and persistance of maximum impair

ment of phagocytic activity in vivo was similar for both
macrophage toxins.

Maximum suppression was observed

approximately 6 h after the administration of either toxin
and recovery to a normal level of phagocytic activity oc
curred after 5 days.

Extensive analysis in vivo and in

vitro by other parameters also indicated that mice exposed
114
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to MUS or carrageenan had impaired phagocytic activity.
The kinetics of the primary immune response to LPS
were evaluated in mice treated with macrophage toxins.
Mice immunized with LPS during macrophage impairment were
capable of producing antibody responses equivalent to those
obtained in normal mice.

There was no change in either the

kinetics or magnitude of the antibody response in mice im
munized during impaired macrophage activity.

These results

suggested that macrophages were not a critical cellular com
ponent for the induction of humoral antibody responses to
the T-cell independent LPS antigen.
The kinetics of the primary immune response to SRBG
were evaluated in mice treated with macrophage toxins.

It

was demonstrated that mice immunized with SRBG during macro
phage impairment were capable of producing antibody re
sponses equivalent to or higher than those obtained in
normal mice.

Macrophage-impaired mice immunized with a low

dose of SRBG (0.2 ml of 0.05^ SRBG) generated higher titers
and demonstrated circulating antibodies 24 h earlier than
normal mice.

Macrophage-impaired mice immunized with an

intermediate dose of SRBG (0.2 ml of 1% SRBG) responded with
the generation of both IgM and IgG class antibodies.
Whereas, normal mice responded to this intermediate dose of
SRBG with only IgM class antibodies.
antibody produced was

Thus, the class of

dependent upon the immunizing dose
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of antigen as well as the functional macrophage population.
These results suggested that macrophages were not essential
for the induction of humoral antibody responses to the
T-cell dependent SRBG antigen, in vivo.

However, it appear

ed that macrophages might compete with other cells for the
quantity of antigen available for lymphocyte stimulation or
that the macrophages suppressed proliferation of antigenstimulated lymphocytes in normal mice.
Typical secondary antibody responses appeared to have
been elicited from mice treated with MUS or carrageenan 6 h
prior to primary immunization.

Mice primed with varying

doses to LPS during macrophage impairment and followed with
a standard secondary dose of LPS 21 days later responded
with a typical quantitative increase of IgM class antibodies.
Mice immunized with varying doses of SRBG during macrophage
impairment and 21 days later injected with a standard
secondary dose of SRBG responded with a typical quantita
tive increase of predominately IgG class antibodies.

There

fore, a reduction in the number of functional macrophages
had not impaired the ability of mice to prime for secondary
antibody responses.
In the course of running controls on the effects of
MUS and carrageenan on priming for a secondary antibody re
sponse several observations were made.

Mice treated with

either toxin 21 days prior to immunization with SRBG de
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veloped higher than normal primary antibody responses to
SRBC,

It was determined that macrophage-impaired mice re

sponded with antibodies of only the IgM class.

However,

the antibody response of normal mice was dependent upon the
dose of SIÎBC administered.

Normal mice responded to a high

dose of SRBC (0.2 ml of 10$ SRBC) with both IgM and IgG
class antibodies; with a low dose of SRBC (0.2 ml of a
0.5$ SRBC) only antibodies of the IgM class were generated.
More interesting were the observations made when one
dose of LPS was given to mice exposed to macrophage toxins
21 days prior to immunization with BPS'.

It was noted that

a secondary type antibody response could be elicited with
only one dose of antigen.

From correlation of hemagglutina

tion titers and PFC data, it appeared that this response
might be due to increased antibody production in committed
lymphocytes rather than the development or expansion of a
memory cell population.

These secondary type antibody re

sponses were not evaluated further.
It was also observed that immunization during macro
phage impairment appeared to prolong the macroglobulin re
sponse to both LPS and SRBC antigens.

Consistently higher

titers with evidence of IgM class antibodies were detected
in macrophage-impaired mice 21 days after immunization with
a single dose of LPS or SRBC.

Thus, it appeared that the

rate and duration of IgM production might be altered in
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mice exposed to macrophage toxins prior to immunization.
In summary, it appeared that macrophages were not
critical cellular components of the ARU,

It was demonstra

ted in the present study that the induction of primary
antibody responses, as well as the priming for secondary
antibody responses, did not appear to be macrophage
dependent.

Prom the data obtained it appeared that macro

phages might function in vivo by sequestering antigen and,
thereby controlling the amount of antigen available for
activation of other immunologically active cells rather
than by increasing the immunogenicity of an antigen by some
critical processing event.
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